Pr GHIRINGHELLI François

The double face of IL-1β in lung cancer.

Rébé C, Perrichet A, Ghiringhelli F

Oncoimmunology. 2026 12 31;15(1):2622661

Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer.

Ghiringhelli F, Kim R, Macarulla T, Moreno I, Abdul Razak A, Rodon Ahnert J, Liao CY, Davis SL, Mahipal A, Marron T, Raimbourg J, Kaplon H, Geronimi J, Harouki N, Rodrigues C, Darcel P, Jakobsen JS, Skartved N, Hald R, Lopez-Ravnborg D, He P, Ianopoulos X, Askoxylakis V, Lakhani N

J Immunother Cancer. 2026 03 13;14(3):

Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.

Walter TP, Mazieres J, Otto J, Lena H, Lepage C, Smith D, Madelaine J, Gérinière L, Egenod T, El Hajbi F, Ferru A, Clément-Duchene C, Madroszyk A, Brotelle T, Bouhier-Leporrier K, Desrame J, Ghiringhelli F, Paleiron N, Khalil A, Milot L, Chevallier O, Couvelard A, Lantuejoul S, Langlais A, Morin F, Duruisseaux M, Michel P, Louvet C, Westeel V, Girard N,

J Clin Oncol. 2026 03 3;:JCO2501657

Phosphatidylcholine and CHPT1 as Central Drivers of Chemoresistance in Colorectal Cancer: Lipidomic and Functional Insights.

Mialhe A, Pais de Barros JP, Hermetet F, Limagne E, Ghiringhelli F, Aires V, Delmas D

Cells. 2026 02 28;15(5):

Deep learning-based assessment of PD-L1 expression in NSCLC predicts outcome for patients treated with anti-PD-1 immunotherapy.

Peroz M, Roussot N, Ilie A, Rageot D, Derangere V, Truntzer C, Ghiringhelli F

Front Immunol. 2026 02 13;17:1750816

The promise of IL-1β modulation in NSCLC clinical context.

Ghiringhelli F, Rébé C

Front Immunol. 2026 01 30;17:1773253

Stearoyl-CoA desaturase-1 controls the differentiation and antitumoral function of Th9 lymphocytes.

Groetz E, Perrey S, Baeza Garcia A, Dumont A, Pichon L, Kieu CTLV, Pierre L, Thomas C, Flavell R, Limagne E, Vegran F, Apetoh L, Ghiringhelli F, Rialland M

J Immunother Cancer. 2026 01 16;14(1):

Circulating transcriptome analysis finds gene signatures and immune cell activation and abundance predict response to immunotherapy in bladder cancer.

Chevrier S, Richard C, Adotévi O, Ayyoub M, Chaput N, Damotte D, Ghiringhelli F, Hacein-Bey-Abina S, Tartour E, Zitvogel L, Marabelle A, Boidot R

Clin Cancer Res. 2026 01 13;:

Sensitive cell-free DNA assay for accurate detection of RAS and BRAF mutations in liquid biopsies of patients with metastatic colorectal cancer: Final results of the multicentric ColoBEAM study.

Harlé A, Gavoille C, Bouché O, Abdelghani MB, Plaza J, Spaeth D, Boudrant A, Ghiringhelli F, Villing AL, Borg C, Rouyer M, Husson M, Gilson P, Salleron J, Lambert A, Merlin JL

Oncol Lett. 2026 01;31(1):13

HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas.

Filippini DM, Cabarrou B, Dupain C, Halladjian M, Coquan E, Sablin MP, Mazzarella L, Francisco M, Servant N, Tonini MM, Hundt AF, Castel-Ajgal Z, You B, Bigot F, Ghiringhelli F, Vansteene D, Gomez-Roca C, Cousin S, Lambert A, Saada-Bouzid E, Durando X, Abdeddaim C, Borel C, Chaltiel R, Borcoman E, Legrand F, Bernhart S, Jimenez M, Bièche I, Filleron T, Le Tourneau C, Kamal M, Jeannot E

ESMO Open. 2025 12 29;11(1):106024

Cancer-associated fibroblasts and their prognostic role in colorectal cancer: review and meta-analysis.

Ilie SM, Gales L, Musina AM, Rouet K, Stefan AE, Belceanu MS, Trandafir AS, Guillaume C, Bertaut A, Charifi I, Cueff A, Derangère V, Ghiringhelli F

Front Oncol. 2025 12 10;15:1635055

Surrogate markers of intestinal dysfunction associated with survival in advanced cancers.

Birebent R, Drubay D, Alves Costa Silva C, Marmorino F, Vitali G, Piccinno G, Hurtado Y, Bonato A, Belluomini L, Messaoudene M, Routy B, Fidelle M, Zalcman G, Mazieres J, Audigier-Valette C, Moro-Sibilot D, Goldwasser F, Scherpereel A, Pegliasco H, Ghiringhelli F, Reni A, Barlesi F, Albiges L, Planchard D, Martinez S, Besse B, Segata N, Cremolini C, Zitvogel L, Iebba V, Derosa L

Oncoimmunology. 2025 12;14(1):2484880

Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancer.

Perrichet A, Lecuelle J, Limagne E, Thiefin M, Bellio H, Jacob P, Aucagne R, Aznague A, Russo P, Gaucher F, Roussot N, Yang X, Vernet T, Nuttin L, Ilie A, Rageot D, Derangère V, Huppe T, Zippelius A, Routy B, Truntzer C, Chalmin F, Ghiringhelli F, Rébé C

Nat Commun. 2025 11 21;16(1):10244

Tumor-Associated Macrophages Produce PGE2 to Promote CD8+ T Cell Exhaustion and Drive Resistance to PD-L1 Blockade in Microsatellite Stable Colorectal Cancer.

Fumet JD, Latour C, Nuttin L, Derangère V, Ilie A, Russo P, Hampe L, Daumoine S, Thibaudin M, Truntzer C, Ghiringhelli F, Limagne E

Cancer Res. 2025 11 6;:

Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial.

Kim S, Boustani J, Iseas S, Vernerey D, Evesque L, Quero L, Ghiringhelli F, Coutzac C, Bouché O, Chibaudel B, Vernet C, Vienot A, Tougeron D, Nguyen T, Rebucci-Peixoto M, Meurisse A, Chennoufi S, Maritaz C, Borg C,

Lancet Oncol. 2025 11 4;:

Epidemiological Classification Changes and Incidence of Early-Onset Colorectal Cancer.

Jooste V, Nousbaum JB, Alves A, Woronoff AS, Launoy G, Molinié F, Desandes E, Delafosse P, Tretarre B, Mercier E, Lepage C, Ghiringhelli F, Bouvier AM,

JAMA Netw Open. 2025 11 3;8(11):e2541732

Interleukin-1β and cancer immune response.

Rébé C, Ghiringhelli F

Semin Immunol. 2025 11 1;80:102002

Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5.

Gazzah A, Ricordel C, Italiano A, Cho BC, Calvo E, Kim DW, Helissey C, Kim JS, Villar MV, Ghiringhelli F, Moreno V, Cousin S, Paz-Ares L, Fagniez N, Chadjaa M, Bauchet AL, Soufflet C, Masson N, Barlesi F

JTO Clin Res Rep. 2025 10;6(10):100844

Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).

Yang JC, Wang M, Doucet L, Fan Y, Lv D, Sun M, Huang D, Greillier L, Planchard D, Hong Q, Mazieres J, Felip E, Li X, Hu Y, Fang J, Bazhenova L, Ghiringhelli F, Cobo Dols MA, Rodriguez LP, Bearz A, Pellini B, Kim YJ, Bosch-Barrera J, Shim BY, Luo YH, Tiseo M, Yang TY, Carcereny E, Memmott RM, Zalcman G, de Castro Carpeno J, Di Noia V, Parra HS, Streich G, Lee DH, Shum E, Han JY, Jaime JC, Brungs D, John T, D'Arcangelo M, Joaquin AB, Liu G, Antonuzzo L, Hinojal GF, Le X, Zheng L, Jänne PA,

J Clin Oncol. 2025 09 9;:JCO2500788

Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung stu

Ghiringhelli F, Lawrence YR, Felip E, Zer A, Greillier L, Greystoke A, Pardo N, Al-Sakaff N, Helms HJ, Prizant H, Pintoffl J, Lim FL, Lim SM, Cho BC

J Immunother Cancer. 2025 08 4;13(8):

Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO.

Dasari A, Eng C, Lonardi S, Garcia-Carbonero R, Masuishi T, Cremolini C, Ghiringhelli F, Hubbard J, Bekaii-Saab T, Jones J, Xu RH, Shen L, Xu J, Bai Y, Deng Y, Yuan Y, Wei W, Lin J, Chen L, Yang Z, Schelman WR, Qin S, Li J

Eur J Cancer. 2025 07 13;227:115641

Co-targeting TGF-β and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet.

Kalfeist L, Ledys F, Petit S, Poirrier C, Kada Mohammed S, Galland L, Derangère V, Ilie A, Rageot D, Aucagne R, Bellaye PS, Truntzer C, Thibaudin M, Rialland M, Ghiringhelli F, Limagne E, Ladoire S

J Clin Invest. 2025 07 1;135(13):

Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial.

Borcoman E, Cabarrou B, Francisco M, Bigot F, Ghiringhelli F, Vansteene D, Legrand F, Halladjian M, Dupain C, Le Saux O, Coutzac C, Borel C, Chaltiel R, You B, Gomez-Roca C, Cousin S, Coquan E, Lambert A, Saada-Bouzid E, Durando X, Saint-Ghislain M, Frige G, Guerini-Rocco E, Tonini MM, Bièche I, Castel-Ajgal Z, Marret G, Sablin MP, Jeannot E, Andre F, Filleron T, Jimenez M, Mazzarella L, Servant N, Kamal M, Le Tourneau C

Nat Cancer. 2025 06 30;:

UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity.

Laheurte C, Boullerot L, Ndao B, Malfroy M, Queiroz L, Guillaume P, Loyon R, Seffar E, Gravelin E, Renaudin A, Jacquin M, Meurisse A, Vernerey D, Ghiringhelli F, Godet Y, Genoley R, Jandus C, Borg C, Adotévi O

Cell Rep Med. 2025 06 17;:102196

Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation.

Xu Y, Yang JC, Zhao Y, Doucet L, Zhou J, Wang Y, Planchard D, Fan Y, Jin B, Han Z, Greillier L, Mazieres J, Sun M, Hu Y, Song X, Ding C, Wu L, Tang K, Liang L, Yao Y, Cheng Y, He Y, Ferreira BP, Ghiringhelli F, Felip E, Bosch-Barrera J, Liu A, Yu Y, Dong X, Gao J, Camidge DR, Nian W, Zhou C, Yang R, John T, Gao B, Bazhenova L, Nagasaka M, Wang J, Ren X, Xu F, Li W, Zhao D, Wang H, Sun S, Huang J, Zhu X, Zheng L, Jänne PA, Wang M

Cell Rep Med. 2025 04 29;:102121

The intrinsic expression of NLRP3 in Th17 cells promotes their protumor activity and conversion into Tregs.

Accogli T, Hibos C, Milian L, Geindreau M, Richard C, Humblin E, Mary R, Chevrier S, Jacquin E, Bernard A, Chalmin F, Paul C, Ryffel B, Apetoh L, Boidot R, Bruchard M, Ghiringhelli F, Vegran F

Cell Mol Immunol. 2025 04 7;:

NIR-II aza-BODIPY Platform for the Development of a Fluorescent Antibody Drug Conjugate.

Chazeau E, Pipier A, Wegner KD, Ghiringhelli F, Sancey L, Paul C, Goze C

J Med Chem. 2025 03 28;:

Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies.

Roussot N, Kaderbhai C, Ghiringhelli F

Cancers (Basel). 2025 03 6;17(5):

Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC.

Cuvelier C, Brahmi M, Sobhani I, Verret B, Grancher A, Penel N, Toulmonde M, Lahlou W, Dupuis H, Calavas L, Muller M, Watson S, Bruyat D, Poumeaud F, Chaigneau L, Manfredi S, Lecomte T, Bertucci F, Ghiringhelli F, Pracht M, Mourthadhoi F, Monceau-Baroux L, Helyon M, Kurtz JE, Roquin G, Regenet N, Vinches M, Tougeron D, Wolkenstein P, Blay JY, Bouche O, Hautefeuille V

ESMO Open. 2025 03 4;10(3):104477

Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer.

Talpin A, Maia A, Carpier JM, Kulakowski G, Aubergeon L, Kervevan J, Gaal C, Strozzi F, Billerey C, Amable L, Mersceman T, Garnier A, Oliveira C, Calderon C, Bachrouche D, Ventujol C, Bernard L, Manteau A, Martinez J, Bonnet M, Noguerol J, Laviolette K, Boullerot L, Malfroy M, Chevalier G, Adotevi O, Joffre O, Idbaih A, Vieito M, Ghiringhelli F, Stradella A, Tabatabai G, Burger MC, Mildenberger I, Herrlinger U, Reardon DA, Wick W, Gouttefangeas C, Bonny C, Chene L, Gamelas Magalhaes J

J Immunother Cancer. 2025 02 20;13(2):

FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trial.

Bellio H, Roussot N, Bertaut A, Hervieu A, Zanetta S, Tharin Z, Vincent J, Bengrine L, Hennequin A, Guion JF, Boudrant A, Collot T, Ghiringhelli F, Fumet JD

Future Oncol. 2025 02 6;:1-8

Deep learning uncovers histological patterns of YAP1/TEAD activity related to disease aggressiveness in cancer patients.

Schmauch B, Cabeli V, Domingues OD, Le Douget JE, Hardy A, Belbahri R, Maussion C, Romagnoni A, Eckstein M, Fuchs F, Swalduz A, Lantuejoul S, Crochet H, Ghiringhelli F, Derangere V, Truntzer C, Pass H, Moreira AL, Chiriboga L, Zheng Y, Ozawa M, Howitt BE, Gevaert O, Girard N, Rexhepaj E, Valtingojer I, Debussche L, de Rinaldis E, Nestle F, Spanakis E, Fantin VR, Durand EY, Classe M, Von Loga K, Pronier E, Cesaroni M

iScience. 2025 01 17;28(1):111638

Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial.

Thibaudin M, Roussot N, Burlot C, Schmitt A, Vincent J, Tharin Z, Bengrine L, Bellio H, Bertaut A, Hampe L, Daumoine S, Rederstorff E, Peroz M, Huppe T, Derangère V, Rageot D, Simard J, Truntzer C, Fumet JD, Ghiringhelli F

Signal Transduct Target Ther. 2025 01 17;10(1):22

Nanostructured lipid carriers based mRNA vaccine leads to a T cell-inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour model.

Fournier C, Mercey-Ressejac M, Derangère V, Al Kadi A, Rageot D, Charrat C, Leroy A, Vollaire J, Josserand V, Escudé M, Escaich S, Ghiringhelli F, Decaens T, Navarro FP, Jouvin-Marche E, Marche PN

EBioMedicine. 2025 01 9;112:105543

Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC.

Rolfo C, Greillier L, Veillon R, Badin F, Ghiringhelli F, Isambert N, Paulus A, Chaudhary SP, Vugmeyster Y, Sato M, Hiret S

JTO Clin Res Rep. 2025 01;6(1):100748

Factors Influencing the Duration of Maintenance Therapy in Metastatic Colorectal Cancer.

Fourrier T, Truntzer C, Peroz M, Derangère V, Vincent J, Bengrine-Lefèvre L, Hennequin A, Palmier R, Orry D, Rabel T, Ghiringhelli F

Cancers (Basel). 2024 12 30;17(1):

Plasma clearance of 5-fluorouracil is more influenced by variations in glomerular filtration rate than by uracil concentration.

Matheux A, Collas L, Grisard M, Goulaieff L, Ghiringhelli F, Bengrine-Lefevre L, Vincent J, Goirand F, Royer B, Schmitt A

Cancer Chemother Pharmacol. 2024 12 19;95(1):9

Deep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery.

Truntzer C, Ouahbi D, Huppé T, Rageot D, Ilie A, Molimard C, Beltjens F, Bergeron A, Vienot A, Borg C, Monnien F, Bibeau F, Derangère V, Ghiringhelli F

Biomedicines. 2024 12 2;12(12):

Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer.

Fumet JD, Roussot N, Bertaut A, Limagne E, Thibaudin M, Hervieu A, Zanetta S, Borg C, Senellart H, Pernot S, Thuillier F, Carnot A, Mineur L, Chibaudel B, Touchefeu Y, Martin-Babau J, Jary M, Labourey JL, Rederstorff E, Lepage C, Ghiringhelli F

Future Oncol. 2024 11 12;:1-9

Real-world comparison of chemo-immunotherapy and chemotherapy alone in the treatment of extensive-stage small-cell lung cancer.

Lamy D, Mouillot P, Mariet A, Barnestein R, Quilot F, Fraisse C, Ghiringhelli F, Bonniaud P, Zouak A, Foucher P

Respir Med Res. 2024 11;86:101125

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.

Kacimi SEO, Dehais C, Feuvret L, Chinot O, Carpentier C, Bronnimann C, Vauleon E, Djelad A, Cohen-Jonathan Moyal E, Langlois O, Campone M, Ducloie M, Noel G, Cuzzubbo S, Taillandier L, Ramirez C, Younan N, Menei P, Dhermain F, Desenclos C, Ghiringhelli F, Bourg V, Ricard D, Faillot T, Appay R, Tabouret E, Nichelli L, Mathon B, Thomas A, Tran S, Bielle F, Alentorn A, Iorgulescu JB, Boëlle PY, Labreche K, Hoang-Xuan K, Sanson M, Idbaih A, Figarella-Branger D, Ducray F, Touat M,

J Clin Oncol. 2024 10 2;:JCO2400049

AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients With MTAP-Deleted Cancers.

Belmontes B, Slemmons KK, Su C, Liu S, Policheni AN, Moriguchi J, Tan H, Xie F, Aiello DA, Yang Y, Lazaro R, Aeffner F, Rees MG, Ronan MM, Roth JA, Vestergaard M, Cowland S, Andersson J, Sarvary I, Chen Q, Sharma P, Lopez P, Tamayo N, Pettus LH, Ghimire-Rijal S, Mukund S, Allen JR, DeVoss J, Coxon A, Rodon J, Ghiringhelli F, Penel N, Prenen H, Glad S, Chuang CH, Keyvanjah K, Townsley DM, Butler JR, Bourbeau MP, Caenepeel S, Hughes PE

Cancer Discov. 2024 09 16;:

The DAV132 colon-targeted adsorbent does not interfere with plasma concentrations of antibiotics but prevents antibiotic-related dysbiosis: a randomized phase I trial in healthy volunteers.

Messaoudene M, Ferreira S, Saint-Lu N, Ponce M, Truntzer C, Boidot R, Le Bescop C, Loppinet T, Corbel T, Féger C, Bertrand K, Elkrief A, Isaksen M, Vitry F, Sablier-Gallis F, Andremont A, Bod L, Ghiringhelli F, de Gunzburg J, Routy B

Nat Commun. 2024 09 15;15(1):8083

Targeting mTOR signaling for the treatment of intrahepatic cholangiocarcinoma with TSC1/ARID1A mutations: a case report with an unexpected response.

Daugan C, Boidot R, Ghiringhelli F, Borg C, Vienot A

Ther Adv Med Oncol. 2024 09 13;16:17588359241271793

Clinical Interest in Exome-Based Analysis of Somatic Mutational Signatures for Non-Small Cell Lung Cancer.

Peroz M, Mananet H, Roussot N, Kaderbhai CG, Derangère V, Truntzer C, Ghiringhelli F

Cancers (Basel). 2024 09 9;16(17):

Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients.

Assaf I, Bregni G, Anthoine G, Aparicio T, Artru P, Abdelghani MB, Buyse M, Chibaudel B, Coart E, Diaz M, Evrard C, Geboes K, Ghiringhelli F, Puleo F, Raimbourg J, Vandamme T, Van den Eynde M, Hendlisz A, Sclafani F

Clin Colorectal Cancer. 2024 09 3;:

First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase 1 dose exploration.

Rodon J, Prenen H, Sacher A, Villalona-Calero M, Penel N, El Helali A, Rottey S, Yamamoto N, Ghiringhelli F, Goebeler ME, Doi T, Postel-Vinay S, Lin CC, Liu C, Chuang CH, Keyvanjah K, Eggert T, O'Neil BH

Ann Oncol. 2024 09 2;:

Natural Killer cells at the frontline in the fight against cancer.

Coënon L, Geindreau M, Ghiringhelli F, Villalba M, Bruchard M

Cell Death Dis. 2024 08 23;15(8):614

Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, co-mutated metastatic NSCLC.

Roussot N, Thibaudin M, Fumet JD, Daumoine S, Hampe L, Rébé C, Limagne E, Lagrange A, Herreros V, Lecuelle J, Mananet H, Ilie A, Rageot D, Boidot R, Goussot V, Comte A, Jacob P, Beltjens F, Bergeron A, Charon-Barra C, Arnould L, Derangère V, Ladoire S, Truntzer C, Ghiringhelli F

Front Immunol. 2024 08 7;15:1437961

Efficacy of novel allogeneic cancer cells vaccine to treat colorectal cancer.

Alzeeb G, Tortorelli C, Taleb J, De Luca F, Berge B, Bardet C, Limagne E, Brun M, Chalus L, Pinteur B, Bravetti P, Gongora C, Apetoh L, Ghiringhelli F

Front Oncol. 2024 07 24;14:1427428

Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study.

Adenis A, Ghiringhelli F, Gauthier L, Mazard T, Evesque L, Evrard A, Chalbos P, Moussion A, Gourgou S, Ychou M

Cancer Chemother Pharmacol. 2024 07 10;:

Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome.

Derosa L, Iebba V, Silva CAC, Piccinno G, Wu G, Lordello L, Routy B, Zhao N, Thelemaque C, Birebent R, Marmorino F, Fidelle M, Messaoudene M, Thomas AM, Zalcman G, Friard S, Mazieres J, Audigier-Valette C, Sibilot DM, Goldwasser F, Scherpereel A, Pegliasco H, Ghiringhelli F, Bouchard N, Sow C, Darik I, Zoppi S, Ly P, Reni A, Daillère R, Deutsch E, Lee KA, Bolte LA, Björk JR, Weersma RK, Barlesi F, Padilha L, Finzel A, Isaksen ML, Escudier B, Albiges L, Planchard D, André F, Cremolini C, Martinez S, Besse B, Zhao L, Segata N, Wojcik J, Kroemer G, Zitvogel L

Cell. 2024 06 20;187(13):3373-3389.e16

Machine learning evaluation of immune infiltrate through digital tumour score allows prediction of survival outcome in a pooled analysis of three international stage III colon cancer cohorts.

Lecuelle J, Truntzer C, Basile D, Laghi L, Greco L, Ilie A, Rageot D, Emile JF, Bibeau F, Taïeb J, Derangere V, Lepage C, Ghiringhelli F

EBioMedicine. 2024 06 15;105:105207

Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors.

Berland L, Gabr Z, Chang M, Ilié M, Hofman V, Rignol G, Ghiringhelli F, Mograbi B, Rashidian M, Hofman P

Front Immunol. 2024 06 5;15:1384121

Interleukin-1α as a Potential Prognostic Biomarker in Pancreatic Cancer.

Gigante L, Gaudillière-Le Dain G, Bertaut A, Truntzer C, Ghiringhelli F

Biomedicines. 2024 05 30;12(6):

Effect of radiochemotherapy on peripheral immune response in glioblastoma.

Hampe L, Daumoine S, Limagne E, Roussot N, Borsotti F, Vincent J, Ilie S, Truntzer C, Ghiringhelli F, Thibaudin M

Cancer Immunol Immunother. 2024 05 16;73(7):133

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.

Kim S, Ghiringhelli F, de la Fouchardière C, Evesque L, Smith D, Badet N, Samalin E, Lopez-Trabada Ataz D, Parzy A, Desramé J, Baba Hamed N, Buecher B, Tougeron D, Bouché O, Dahan L, Chibaudel B, El Hajbi F, Mineur L, Dubreuil O, Ben Abdelghani M, Pecout S, Bibeau F, Herfs M, Garcia ML, Meurisse A, Vernerey D, Taïeb J, Borg C

Lancet Oncol. 2024 04;25(4):518-528

Targeting two radiation-induced immunosuppressive pathways to improve the efficacy of normofractionated radiation therapy in a preclinical colorectal cancer model.

Boustani J, Lecoester B, Baude J, Latour C, Limagne E, Ladjohoulou R, Morgand V, Froidurot L, Ghiringhelli F, Truc G, Adotévi O, Mirjolet C

Int J Radiat Biol. 2024 03 20;:1-10

Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study.

De La Fouchardière C, Malka D, Cropet C, Chabaud S, Raimbourg J, Botsen D, Launay S, Evesque L, Vienot A, Perrier H, Jary M, Rinaldi Y, Coutzac C, Bachet JB, Neuzillet C, Williet N, Desgrippes R, Grainville T, Aparicio T, Peytier A, Lecomte T, Roth GS, Thirot-Bidault A, Lachaux N, Bouché O, Ghiringhelli F

J Clin Oncol. 2024 01 17;:JCO2300795

CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy.

Schoumacher C, Derangère V, Gaudillière-Le Dain G, Huppe T, Rageot D, Ilie A, Vienot A, Borg C, Monnien F, Bibeau F, Truntzer C, Ghiringhelli F,

Oncoimmunology. 2023 12 21;13(1):2294563

Targeting CTLA-4: a possible solution for microsatellite-stable colorectal cancer.

Ghiringhelli F, Thibaudin M

Genes Immun. 2023 12 8;:

FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy.

Roussot N, Vincent J, Palmier R, Constantin G, Bengrine L, Fumet JD, Ghiringhelli F

Front Oncol. 2023 11 30;13:1293670

A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.

Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C

BMC Cancer. 2023 11 9;23(1):1080

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Buisseret L, Loirat D, Aftimos P, Maurer C, Punie K, Debien V, Kristanto P, Eiger D, Goncalves A, Ghiringhelli F, Taylor D, Clatot F, Van den Mooter T, Ferrero JM, Bonnefoi H, Canon JL, Duhoux FP, Mansi L, Poncin R, Barthélémy P, Isambert N, Denis Z, Catteau X, Salgado R, Agostinetto E, de Azambuja E, Rothé F, Craciun L, Venet D, Romano E, Stagg J, Paesmans M, Larsimont D, Sotiriou C, Ignatiadis M, Piccart-Gebhart M

Nat Commun. 2023 11 2;14(1):7018

Protocol for simultaneous analysis of peripheral and intratumoral lymphocyte function by flow cytometry.

Daumoine S, Hampe L, Limagne E, Ghiringhelli F, Thibaudin M

STAR Protoc. 2023 10 31;4(4):102658

Evaluation of immune infiltrate according to the HER2 status in colorectal cancer.

Molimard C, Dor F, Overs A, Monnien F, Gessain G, Kedochim L, D'Angelo F, Abad M, Heberle M, Derangère V, Ghiringhelli F, Vuitton L, Valmary-Degano S, Borg C, Lakkis Z, Bibeau F

Dig Liver Dis. 2023 10 14;:

FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report.

Roussot N, Lecuelle J, Dalens L, Truntzer C, Ghiringhelli F

J Immunother Cancer. 2023 10;11(10):

Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer.

Thibaudin M, Ghiringhelli F

Oncoimmunology. 2023 09 15;12(1):2257098

Advancing precision oncology through systematic germline and tumor genetic analysis: The oncogenetic point of view on findings from a prospective multicenter clinical trial of 666 patients.

Mazel B, Bertolone G, Baurand A, Cosset E, Sawka C, Robert M, Gautier E, Lançon A, Réda M, Favier L, Dérangère V, Richard C, Binquet C, Boidot R, Goussot V, Albuisson J, Ghiringhelli F, Faivre L, Nambot S

Cancer Med. 2023 09 11;:

Using immunogenic cell death to improve anticancer efficacy of immune checkpoint inhibitors: From basic science to clinical application.

Ghiringhelli F, Rébé C

Immunol Rev. 2023 08 18;:

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.

Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derangère V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F

Nat Med. 2023 08 10;:

Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).

Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat E, Hammel P, Rosmorduc O, Stouvenot M, Allaire M, Bouattour M, Regnault H, Fratte S, Raymond E, Soularue E, Husson-Wetzel S, Di Martino V, Muller A, Clairet AL, Fagnoni-Legat C, Adotevi O, Meurisse A, Vernerey D, Borg C

BMC Cancer. 2023 07 29;23(1):710

DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study.

Kim S, Vendrely V, Saint A, André T, Vaflard P, Samalin E, Pernot S, Bouché O, Zubir M, Desrame J, de la Fouchardière C, Smith D, Ghiringhelli F, Vienot A, Jacquin M, Klajer E, Nguyen T, François É, Taieb J, Le Malicot K, Vernerey D, Meurisse A, Borg C

Exp Hematol Oncol. 2023 07 21;12(1):63

Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.

Marolleau P, Tougeron D, Allignet B, Cohen R, Sefrioui D, Gallet B, Dumont F, Guimbaud R, Alouani E, Passot G, Desolneux G, Ghiringhelli F, Marchal F, Mourthadhoi F, Coriat R, Desgrippes R, Locher C, Goujon G, Des Guetz G, Aparicio T, Paubelle E, Dupré A, de la Fouchardière C

Int J Cancer. 2023 07 5;:

Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency.

Schmitt A, Royer B, Boidot R, Berthier J, Ghiringhelli F

Front Oncol. 2023 06 20;13:1187052

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.

Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csőszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C,

Lancet. 2023 06 15;:

A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers.

Fidelle M, Rauber C, Alves Costa Silva C, Tian AL, Lahmar I, de La Varende AM, Zhao L, Thelemaque C, Lebhar I, Messaoudene M, Pizzato E, Birebent R, Mbogning Fonkou MD, Zoppi S, Reni A, Dalban C, Leduc M, Ferrere G, Durand S, Ly P, Silvin A, Mulder K, Dutertre CA, Ginhoux F, Yonekura S, Roberti MP, Tidjani-Alou M, Terrisse S, Chen J, Kepp O, Schippers A, Wagner N, Suárez-Gosálvez J, Kobold S, Fahrner JE, Richard C, Bosq J, Lordello L, Vitali G, Galleron N, Quinquis B, Le Chatelier E, Blanchard L, Girard JP, Jarry A, Gervois N, Godefroy E, Labarrière N, Koschny R, Daillère R, Besse B, Truntzer C, Ghiringhelli F, Coatnoan N, Mhanna V, Klatzmann D, Drubay D, Albiges L, Thomas AM, Segata N, Danlos FX, Marabelle A, Routy B, Derosa L, Kroemer G, Zitvogel L

Science. 2023 06 9;380(6649):eabo2296

GTN Enhances Antitumor Effects of Doxorubicin in TNBC by Targeting the Immunosuppressive Activity of PMN-MDSC.

Mabrouk N, Racoeur C, Shan J, Massot A, Ghione S, Privat M, Dondaine L, Ballot E, Truntzer C, Boidot R, Hermetet F, Derangère V, Bruchard M, Végran F, Chouchane L, Ghiringhelli F, Bettaieb A, Paul C

Cancers (Basel). 2023 06 9;15(12):

Biliary tract cancers have distinct epidemiological patterns and clinical characteristics according to tumour site.

Ghiringhelli F, Jooste V, Manfredi S, Hennequin A, Lepage C, Bouvier AM

HPB (Oxford). 2023 06;25(6):693-703

Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop.

Clifton GT, Rothenberg M, Ascierto PA, Begley G, Cecchini M, Eder JP, Ghiringhelli F, Italiano A, Kochetkova M, Li R, Mechta-Grigoriou F, Pai SI, Provenzano P, Puré E, Ribas A, Schalper KA, Fridman WH

J Immunother Cancer. 2023 06;11(6):

Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer.

Ghiringhelli F, Bibeau F, Greillier L, Fumet JD, Ilie A, Monville F, Laugé C, Catteau A, Boquet I, Majdi A, Morgand E, Oulkhouir Y, Brandone N, Adam J, Sbarrato T, Kassambara A, Fieschi J, Garcia S, Lepage AL, Tomasini P, Galon J

EBioMedicine. 2023 05 25;92:104633

Radiomics combined with transcriptomics to predict response to immunotherapy from patients treated with PD-1/PD-L1 inhibitors for advanced NSCLC.

Bouhamama A, Leporq B, Faraz K, Foy JP, Boussageon M, Pérol M, Ortiz-Cuaran S, Ghiringhelli F, Saintigny P, Beuf O, Pilleul F

Front Radiol. 2023 05 3;3:1168448

Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma.

Piquemal D, Bruno R, Bournet B, Ghiringhelli F, Noguier F, Canivet C, Bertaut A, Pierrat F, Evesque L, Gamez A, Cros J, Rederstorff E, Petit E, Adnet J, Saint A, Drouillard A, Kempf E, Soularue E, Vincent J, Baumgaertner I, Hennequin A, Tournigand C, Lopez Trabada Ataz D, Bengrine L, Lepage C, Manfredi S, Afchain P, Trouilloud I, Gagnaire A, LoConte NK, Bachet JB

J Gastrointest Oncol. 2023 04 29;14(2):997-1007

Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type.

Dalens L, Lecuelle J, Favier L, Fraisse C, Lagrange A, Kaderbhai C, Boidot R, Chevrier S, Mananet H, Derangère V, Truntzer C, Ghiringhelli F

Int J Mol Sci. 2023 04 20;24(8):

Inflammasome-independent NLRP3 function enforces ATM activity in response to genotoxic stress.

Bodnar-Wachtel M, Huber AL, Gorry J, Hacot S, Burlet D, Gérossier L, Guey B, Goutagny N, Bartosch B, Ballot E, Lecuelle J, Truntzer C, Ghiringhelli F, Py BF, Couté Y, Ballesta A, Lantuejoul S, Hall J, Tissier A, Petrilli V

Life Sci Alliance. 2023 04;6(4):

PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy.

Tharin Z, Richard C, Derangère V, Ilie A, Arnould L, Ghiringhelli F, Boidot R, Ladoire S

Sci Rep. 2023 03 18;13(1):4467

Predictive Factors of Local Recurrence after Colorectal Cancer Liver Metastases Thermal Ablation.

Odet J, Pellegrinelli J, Varbedian O, Truntzer C, Midulla M, Ghiringhelli F, Orry D

J Imaging. 2023 03 10;9(3):

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer.

Galland L, Roussot N, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Reda M, Albuisson J, Arnould L, Boidot R, Truntzer C, Ghiringhelli F, Ladoire S

Cancers (Basel). 2023 02 18;15(4):

The "extreme phenotype approach" applied to male breast cancer allows the identification of rare variants of ATR as potential breast cancer susceptibility alleles.

Chevarin M, Alcantara D, Albuisson J, Collonge-Rame MA, Populaire C, Selmani Z, Baurand A, Sawka C, Bertolone G, Callier P, Duffourd Y, Jonveaux P, Bignon YJ, Coupier I, Cornelis F, Cordier C, Mozelle-Nivoix M, Rivière JB, Kuentz P, Thauvin C, Boidot R, Ghiringhelli F, O'Driscoll M, Faivre L, Nambot S

Oncotarget. 2023 02 7;14:111-125

Simultaneous isolation of CD45 tumor-infiltrating lymphocytes, tumor cells, and associated fibroblasts from murine breast tumor model by MACS.

Kalfeist L, Petit S, Galland L, Ghiringhelli F, Ladoire S, Limagne E

STAR Protoc. 2023 01 18;4(1):101951

SALL4-related gene signature defines a specific stromal subset of pancreatic ductal adenocarcinoma with poor prognostic features.

Vienot A, Monnien F, Truntzer C, Mougey V, Bouard A, Pallandre JR, Molimard C, Loyon R, Asgarov K, Averous G, Ghiringhelli F, Bibeau F, Peixoto P, Borg C

Mol Oncol. 2023 01 1;:

Integrative Clinical and DNA Methylation Analyses in a Population-Based Cohort Identifies and as Risk Recurrence Factors in Stage II Colon Cancer.

Tournier B, Aucagne R, Truntzer C, Fournier C, Ghiringhelli F, Chapusot C, Martin L, Bouvier AM, Manfredi S, Jooste V, Callanan MB, Lepage C

Cancers (Basel). 2022 12 27;15(1):

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial.

de Rauglaudre B, Sibertin-Blanc C, Fabre A, Le Malicot K, Bennouna J, Ghiringhelli F, Taïeb J, Boige V, Bouché O, Chatellier T, Faroux R, François E, Jacquot S, Genet D, Mulot C, Olschwang S, Seitz JF, Aparicio T, Dahan L

Ther Adv Med Oncol. 2022 12 26;14:17588359221141307

Efficacy of Chemotherapy Plus Bevacizumab in Recurrent Glioblastoma Multiform: A Real-life Study.

Beige A, Ghiringhelli F, Lecuelle J, Truntzer C, Truc G, Vincent J, Farah W, Borsotti F, Mazilu I, Ilie SM

Anticancer Res. 2022 12;42(12):5847-5858

Associating immunotherapy and targeted therapies: facts and hopes.

Ladoire S, Rébé C, Ghiringhelli F

Clin Cancer Res. 2022 11 29;:

Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.

Ballot E, Galland L, Mananet H, Boidot R, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S

Breast Cancer Res. 2022 11 18;24(1):80

Tumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment.

Roussot N, Ghiringhelli F, Rébé C

Cells. 2022 11 18;11(22):

Weakly Supervised Learning using Attention gates for colon cancer histopathological image segmentation.

Ben Hamida A, Devanne M, Weber J, Truntzer C, Derangère V, Ghiringhelli F, Forestier G, Wemmert C

Artif Intell Med. 2022 11;133:102407

Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors.

Foy JP, Karabajakian A, Ortiz-Cuaran S, Boussageon M, Michon L, Bouaoud J, Fekiri D, Robert M, Baffert KA, Hervé G, Quilhot P, Attignon V, Girod A, Chaine A, Benassarou M, Zrounba P, Caux C, Ghiringhelli F, Lantuejoul S, Crozes C, Brochériou I, Pérol M, Fayette J, Bertolus C, Saintigny P

Data Brief. 2022 10;44:108556

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.

Barnestein R, Galland L, Kalfeist L, Ghiringhelli F, Ladoire S, Limagne E

Oncoimmunology. 2022 09 13;11(1):2120676

Downregulation of Elovl5 promotes breast cancer metastasis through a lipid-droplet accumulation-mediated induction of TGF-β receptors.

Kieu TL, Pierre L, Derangère V, Perrey S, Truntzer C, Jalil A, Causse S, Groetz E, Dumont A, Guyard L, Arnould L, de Barros JP, Apetoh L, Rébé C, Limagne E, Jourdan T, Demizieux L, Masson D, Thomas C, Ghiringhelli F, Rialland M

Cell Death Dis. 2022 09 2;13(9):758

Detection of relevant pharmacogenetic information through exome sequencing in oncology.

Verdez S, Albuisson J, Duffourd Y, Boidot R, Reda M, Thauvin-Robinet C, Fumet JD, Ladoire S, Nambot S, Callier P, Faivre L, Ghiringhelli F, Picard N

Pharmacogenomics. 2022 08 31;:

Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients.

Foy JP, Karabajakian A, Ortiz-Cuaran S, Boussageon M, Michon L, Bouaoud J, Fekiri D, Robert M, Baffert KA, Hervé G, Quilhot P, Attignon V, Girod A, Chaine A, Benassarou M, Zrounba P, Caux C, Ghiringhelli F, Lantuejoul S, Crozes C, Brochériou I, Pérol M, Fayette J, Bertolus C, Saintigny P

Eur J Cancer. 2022 08 26;:

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma.

Kim S, Boustani J, Vernerey D, Vendrely V, Evesque L, Francois E, Quero L, Ghiringhelli F, de la Fouchardière C, Dahan L, Bouché O, Chibaudel B, Hajbi FE, Vernet C, Rebucci-Peixoto M, Feuersinger A, Maritaz C, Borg C

Front Oncol. 2022 08 24;12:918499

Interplay between plasmacytoid dendritic cells and tumor-specific T cells in peripheral blood influences long-term survival in non-small cell lung carcinoma.

Laheurte C, Seffar E, Gravelin E, Lecuelle J, Renaudin A, Boullerot L, Malfroy M, Marguier A, Lecoester B, Gaugler B, Saas P, Truntzer C, Ghiringhelli F, Adotevi O

Cancer Immunol Immunother. 2022 08 21;:

Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: a POLA network study.

Seyve A, Dehais C, Chinot O, Djelad A, Cohen-Moyal E, Bronnimann C, Gourmelon C, Emery E, Colin P, Boone M, Vauléon E, Langlois O, di Stefano AL, Seizeur R, Ghiringhelli F, D'Hombres A, Feuvret L, Guyotat J, Capelle L, Carpentier C, Garnier L, Honnorat J, Meyronet D, Mokhtari K, Figarella-Branger D, Ducray F,

Neuro Oncol. 2022 08 12;:

Metronomic Cyclophosphamide With Cisplatin and Bevacizumab for Refractory Anaplastic Ependymoma: A Retrospective Study.

DE Laclos XC, Frappaz D, Ahle G, Bronnimann C, Catry-Thomas I, Joncour A, Ghiringhelli F, Vauleon E

Anticancer Res. 2022 08;42(8):3863-3867

Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.

Coutzac C, Bibeau F, Ben Abdelghani M, Aparicio T, Cohen R, Coquan E, Dubreuil O, Evesque L, Ghiringhelli F, Kim S, Lesourd S, Neuzillet C, Phelip JM, Piessen G, Rochigneux P, Samalin E, Soularue E, Touchefeu Y, Tougeron D, Zaanan A, de la Fouchardière C

Dig Liver Dis. 2022 07 27;:

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study.

Rebucci-Peixoto M, Vienot A, Adotevi O, Jacquin M, Ghiringhelli F, de la Fouchardière C, You B, Maurina T, Kalbacher E, Bazan F, Meynard G, Clairet AL, Fagnoni-Legat C, Spehner L, Bouard A, Vernerey D, Meurisse A, Kim S, Borg C, Mansi L

Front Oncol. 2022 07 19;12:957580

Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.

Derangère V, Lecuelle J, Lepage C, Aoulad-Ben Salem O, Allatessem BM, Ilie A, Bouché O, Phelip JM, Baconnier M, Pezet D, Sebbagh V, Terrebonne E, Bouard G, Jooste V, Bouvier AM, Molimard C, Monnien F, Gonzalez D, Le Malicot K, Rageot D, Truntzer C, Bibeau F, Ghiringhelli F,

Eur J Cancer. 2022 07 1;172:221-230

Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort.

Tankere P, Boidot R, Bonniaud P, Zouak A, Foucher P, Milliere A, Bertaut A, Favier L, Lagrange A, Ghiringhelli F, Kaderbhai CG, Fraisse C

J Thorac Dis. 2022 06;14(6):2034-2044

Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects.

Mary R, Chalmin F, Accogli T, Bruchard M, Hibos C, Melin J, Truntzer C, Limagne E, Derangère V, Thibaudin M, Humblin E, Boidot R, Chevrier S, Arnould L, Richard C, Klopfenstein Q, Bernard A, Urade Y, Harker JA, Apetoh L, Ghiringhelli F, Végran F

Cancer Immunol Res. 2022 05 25;:OF1-OF17

Mitophagy: a new actor in the efficacy of chemo-immunotherapy.

Limagne E, Ghiringhelli F

Autophagy. 2022 May 9;:1-2

Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice.

Jooste V, Bengrine-Lefevre L, Manfredi S, Quipourt V, Grosclaude P, Facy O, Lepage C, Ghiringhelli F, Bouvier AM

Cancers (Basel). 2022 Mar 25;14(7):

Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series.

Niogret J, Derangère V, Richard C, Nuttin L, Ghiringhelli F, Favier L, Lefevre LB, Bergeron A, Arnould L, Boidot R

Int J Mol Sci. 2022 Mar 19;23(6):

Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer.

Thibaudin M, Limagne E, Hampe L, Ballot E, Truntzer C, Ghiringhelli F

Cancer Immunol Immunother. 2022 Mar 16;:

Tumor budding is an independent prognostic factor in stage III colon cancer patients: A post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).

Basile D, Broudin C, Emile JF, Falcoz A, Pagès F, Mineur L, Bennouna J, Louvet C, Artru P, Fratte S, Ghiringhelli F, André T, Derangère V, Vernerey D, Taieb J, Svrcek M,

Ann Oncol. 2022 Mar 16;:

Conception and evaluation of fluorescent phosphine-gold complexes: from synthesis to in vivo investigations.

Rousselle B, Massot A, Privat M, Dondaine L, Trommenschlager A, Bouyer F, Bayardon J, Ghiringhelli F, Bettaieb A, Goze C, Paul C, Malacea-Kabbara R, Bodio E

ChemMedChem. 2022 Mar 7;:

Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing.

Galland L, Ballot E, Mananet H, Boidot R, Lecuelle J, Albuisson J, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S

NPJ Breast Cancer. 2022 Mar 4;8(1):28

Small Cell Neuroendocrine Carcinoma of the Paranasal Sinuses with Unexpected Location and Clinical Presentation and Occupational Exposure: A Case Report.

Tankere P, Zanetta S, Kaderbhai CG, Bellio H, Lagrange A, Garcier M, Ghiringhelli F

Am J Case Rep. 2022 Mar 2;23:e934980

MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer.

Lecuelle J, Favier L, Fraisse C, Lagrange A, Kaderbhai C, Boidot R, Chevrier S, Joubert P, Routy B, Truntzer C, Ghiringhelli F

J Immunother Cancer. 2022 Mar;10(3):

Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era.

Kalfeist L, Galland L, Ledys F, Ghiringhelli F, Limagne E, Ladoire S

Cells. 2022 Feb 22;11(5):

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.

Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, Mazieres J, Audigier-Valette C, Moro-Sibilot D, Goldwasser F, Silva CAC, Terrisse S, Bonvalet M, Scherpereel A, Pegliasco H, Richard C, Ghiringhelli F, Elkrief A, Desilets A, Blanc-Durand F, Cumbo F, Blanco A, Boidot R, Chevrier S, Daillère R, Kroemer G, Alla L, Pons N, Le Chatelier E, Galleron N, Roume H, Dubuisson A, Bouchard N, Messaoudene M, Drubay D, Deutsch E, Barlesi F, Planchard D, Segata N, Martinez S, Zitvogel L, Soria JC, Besse B

Nat Med. 2022 Feb 3;:

Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study.

Ladoire S, Rederstorff E, Goussot V, Parnalland S, Briot N, Ballot E, Truntzer C, Ayati S, Bengrine-Lefevre L, Bremaud N, Coudert B, Desmoulins I, Favier L, Fraisse C, Fumet JD, Hennequin A, Hervieu A, Ilie S, Kaderbhai C, Lagrange A, Martin N, Mazilu I, Mayeur D, Palmier R, Simonet-Lamm AL, Vincent J, Zanetta S, Arnould L, Coutant C, Bertaut A, Ghiringhelli F

Eur J Cancer. 2022 Feb 1;165:13-24

Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses.

Bruchard M, Geindreau M, Perrichet A, Truntzer C, Ballot E, Boidot R, Racoeur C, Barsac E, Chalmin F, Hibos C, Baranek T, Paget C, Ryffel B, Rébé C, Paul C, Végran F, Ghiringhelli F

Nat Immunol. 2022 Feb;23(2):262-274

MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.

Limagne E, Nuttin L, Thibaudin M, Jacquin E, Aucagne R, Bon M, Revy S, Barnestein R, Ballot E, Truntzer C, Derangère V, Fumet JD, Latour C, Rébé C, Bellaye PS, Kaderbhaï CG, Spill A, Collin B, Callanan MB, Lagrange A, Favier L, Coudert B, Arnould L, Ladoire S, Routy B, Joubert P, Ghiringhelli F

Cancer Cell. 2022 Jan 17;:

A natural polyphenol exerts antitumor activity and circumvents anti-PD-1 resistance through effects on the gut microbiota.

Messaoudene M, Pidgeon R, Richard C, Ponce M, Diop K, Benlaifaoui M, Nolin-Lapalme A, Cauchois F, Malo J, Belkaid W, Isnard S, Fradet Y, Dridi L, Velin D, Oster P, Raoult D, Ghiringhelli F, Boidot R, Chevrier S, Kysela DT, Brun YV, Falcone EL, Pilon G, Plaza Onate F, Gitton-Quent O, Le Chatelier E, Durand S, Kroemer G, Elkrief A, Marette A, Castagner B, Routy B

Cancer Discov. 2022 Jan 14;:

Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.

Ychou M, Rivoire M, Thezenas S, Guimbaud R, Ghiringhelli F, Mercier-Blas A, Mineur L, Francois E, Khemissa F, Chauvenet M, Kianmanesh R, Fonck M, Houyau P, Aparicio T, Galais MP, Audemar F, Assenat E, Lopez-Crapez E, Jouffroy C, Adenis A, Adam R, Bouché O

Br J Cancer. 2022 Jan 6;:

Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.

Stouvenot M, Meurisse A, Saint A, Buecher B, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Smith D, Ghiringhelli F, Parzy A, de la Fouchardiere C, Almotlak H, Vienot A, Jacquin M, Taieb J, Nguyen T, Vernerey D, Borg C, Kim S

Eur J Cancer. 2022 Jan 4;162:138-147

MAPK signaling regulates the efficacy of chemoimmunotherapy.

Ghiringhelli F

Mol Cell Oncol. 2022 ;9(1):2054652

Targeting coagulation to unlock antitumor immunity?

Galmiche A, Saidak Z, Ghiringhelli F

Oncoimmunology. 2022 ;11(1):2045696

Using a convolutional neural network for classification of squamous and non-squamous non-small cell lung cancer based on diagnostic histopathology HES images.

Le Page AL, Ballot E, Truntzer C, Derangère V, Ilie A, Rageot D, Bibeau F, Ghiringhelli F

Sci Rep. 2021 Dec 13;11(1):23912

Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients.

Palle J, Hirsch L, Lapeyre-Prost A, Malka D, Bourhis M, Pernot S, Marcheteau E, Voron T, Castan F, Lacotte A, Benhamouda N, Tanchot C, François E, Ghiringhelli F, de la Fouchardière C, Zaanan A, Tartour E, Taieb J, Terme M

Cancers (Basel). 2021 Nov 5;13(21):

Utility of exome sequencing in routine care for metastatic colorectal cancer.

D'Agay MG, Galland L, Tharin Z, Truntzer C, Ghiringhelli F

Mol Clin Oncol. 2021 Nov;15(5):229

Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer.

Bellio H, Bertaut A, Hervieu A, Zanetta S, Hennequin A, Vincent J, Palmier R, Bengrine-Lefevre L, Ghiringhelli F, Fumet JD

Cancers (Basel). 2021 Oct 30;13(21):

Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.

Phelip JM, Desrame J, Edeline J, Barbier E, Terrebonne E, Michel P, Perrier H, Dahan L, Bourgeois V, Akouz FK, Soularue E, Ly VL, Molin Y, Lecomte T, Ghiringhelli F, Coriat R, Louafi S, Neuzillet C, Manfredi S, Malka D,

J Clin Oncol. 2021 Oct 18;:JCO2100679

Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II Study.

Bertaut A, Touchefeu Y, Blanc J, Bouché O, François E, Conroy T, Artru P, Adenis A, Gobbo J, Borg C, Ghiringhelli F, Bennouna J

Clin Colorectal Cancer. 2021 Oct 3;:

A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors.

Oza AM, Dubois F, Hegg R, Hernández CA, Finocchiaro G, Ghiringhelli F, Zamagni C, Nick S, Irahara N, Perretti T, Colombo N

Oncologist. 2021 Sep 9;:

Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer.

Thierry AR, Pastor B, Pisareva E, Ghiringhelli F, Bouché O, De La Fouchardière C, Vanbockstael J, Smith D, François E, Dos Santos M, Botsen D, Ellis S, Fonck M, André T, Guardiola E, Khemissa F, Linot B, Martin-Babau J, Rinaldi Y, Assenat E, Clavel L, Dominguez S, Gavoille C, Sefrioui D, Pezzella V, Mollevi C, Ychou M, Mazard T

JAMA Netw Open. 2021 Sep 1;4(9):e2124483

TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer.

Lecuelle J, Boidot R, Mananet H, Derangère V, Albuisson J, Goussot V, Arnould L, Tharin Z, Ray Coquard I, Ghiringhelli F, Truntzer C, Fumet JD

Cancers (Basel). 2021 Aug 31;13(17):

Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?

Niogret J, Dalens L, Truntzer C, Chevrier S, Favier L, Lagrange A, Coudert B, Fraisse C, Foucher P, Zouak A, Westeel V, Goussot V, Dérangère V, Albuisson J, Arnould L, Boidot R, Kaderbhai CG, Ghiringhelli F

Lung Cancer. 2021 Aug 29;161:98-107

Deep learning for colon cancer histopathological images analysis.

Ben Hamida A, Devanne M, Weber J, Truntzer C, Derangère V, Ghiringhelli F, Forestier G, Wemmert C

Comput Biol Med. 2021 Aug 4;136:104730

Influence of first line chemotherapy strategy depending on primary tumor location in metastatic colorectal cancer.

Tharin Z, Blanc J, Alaoui IC, Bertaut A, Ghiringhelli F

J Gastrointest Oncol. 2021 Aug;12(4):1509-1517

infection has a detrimental impact on the efficacy of cancer immunotherapies.

Oster P, Vaillant L, Riva E, McMillan B, Begka C, Truntzer C, Richard C, Leblond MM, Messaoudene M, Machremi E, Limagne E, Ghiringhelli F, Routy B, Verdeil G, Velin D

Gut. 2021 Jul 12;:

Impact of proton therapy on antitumor immune response.

Mirjolet C, Nicol A, Limagne E, Mura C, Richard C, Morgand V, Rousseau M, Boidot R, Ghiringhelli F, Noel G, Burckel H

Sci Rep. 2021 Jun 29;11(1):13444

Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study.

Deschênes-Simard X, Richard C, Galland L, Blais F, Desilets A, Malo J, Cvetkovic L, Belkaid W, Elkrief A, Gagné A, Hamel MA, Orain M, Joubert P, Ghiringhelli F, Routy B, Blais N

Thromb Res. 2021 Jun 29;205:29-39

Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer.

Galland L, Lecuelle J, Favier L, Fraisse C, Lagrange A, Kaderbhai C, Truntzer C, Ghiringhelli F

Cancers (Basel). 2021 Jun 16;13(12):

ILC2s in cancer: context matters.

Bruchard M, Ghiringhelli F

Nat Immunol. 2021 Jun 7;:

Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer.

Klopfenstein Q, Derangère V, Arnould L, Thibaudin M, Limagne E, Ghiringhelli F, Truntzer C, Ladoire S

J Immunother Cancer. 2021 06;9(6):

Follicular helper-T cells restore CD8-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy.

Niogret J, Berger H, Rebe C, Mary R, Ballot E, Truntzer C, Thibaudin M, Derangère V, Hibos C, Hampe L, Rageot D, Accogli T, Joubert P, Routy B, Harker J, Vegran F, Ghiringhelli F, Chalmin F

J Immunother Cancer. 2021 Jun;9(6):

FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer.

Adenis A, Mazard T, Fraisse J, Chalbos P, Pastor B, Evesque L, Ghiringhelli F, Mollevi C, Delaine S, Ychou M

BMC Cancer. 2021 May 17;21(1):564

Performance of Next Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer with Deficient DNA Mismatch Repair.

Ratovomanana T, Cohen R, Svrcek M, Renaud F, Cervera P, Siret A, Letourneur Q, Buhard O, Bourgoin P, Guillerm E, Dorard C, Nicolle R, Ayadi M, Touat M, Bielle F, Sanson M, Le Rouzic P, Buisine MP, Piessen G, Collura A, Fléjou JF, de Reynies A, Coulet F, Ghiringhelli F, André T, Jonchère V, Duval A

Gastroenterology. 2021 May 13;:

Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment.

Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S, Zitvogel L

Cell Death Differ. 2021 May 7;:

Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response.

Geindreau M, Ghiringhelli F, Bruchard M

Int J Mol Sci. 2021 May 4;22(9):

Targeting BRAF and RAS in Colorectal Cancer.

Bellio H, Fumet JD, Ghiringhelli F

Cancers (Basel). 2021 May 3;13(9):

Development of a novel highly anti-proliferative family of gold complexes: Au(i)-phosphonium-phosphines.

Rousselle B, Bouyer F, Bayardon J, Laly M, Ghiringhelli F, Rousselin Y, Bodio E, Malacea-Kabbara R

Dalton Trans. 2021 Apr 14;50(14):4880-4889

Using Exome Sequencing to Improve Prediction of FOLFIRINOX First Efficacy for Pancreatic Adenocarcinoma.

Lecuelle J, Aarnink A, Tharin Z, Truntzer C, Ghiringhelli F

Cancers (Basel). 2021 Apr 13;13(8):

Hype and hope of hepatic arterial infusion for colorectal cancer.

Ghiringhelli F

Hepatobiliary Surg Nutr. 2021 Apr;10(2):235-237

Incidental findings in a series of 2500 gene panel tests for a genetic predisposition to cancer: Results and Impact on patients.

Nambot S, Bertolone G, Sawka C, Cosset E, Goussot V, Derangère V, Boidot R, Baurand A, Robert M, Coutant C, Loustalot C, Thauvin-Robinet C, Ghiringhelli F, Lançon A, Populaire C, Damette A, Collonge-Rame MA, Meunier-Beillard N, Lejeune C, Albuisson J, Faivre L

Eur J Med Genet. 2021 Mar 19;:104196

Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study.

Ladoire S, Goussot V, Redersdorff E, Cueff A, Ballot E, Truntzer C, Ayati S, Bengrine-Lefevre L, Bremaud N, Coudert B, Desmoulins I, Favier L, Fraisse C, Fumet JD, Hanu R, Hennequin A, Hervieu A, Ilie S, Kaderbhai C, Lagrange A, Martin N, Mazilu I, Mayeur D, Palmier R, Simonet-Lamm AL, Vincent J, Zanetta S, Arnould L, Coutant C, Bertaut A, Ghiringhelli F

Eur J Cancer. 2021 Feb 27;148:359-370

Percutaneous Implantation of a Microcatheter-Port System for Hepatic Arterial Infusion Chemotherapy of Unresectable Liver Tumors: Technical Feasibility, Functionality, and Complications.

Chevallier O, Mvouama S, Pellegrinelli J, Guillen K, Manfredi S, Ghiringhelli F, Falvo N, Midulla M, Loffroy R

Diagnostics (Basel). 2021 Feb 26;11(3):

Transarterial Radioembolization of Hepatocellular Carcinoma, Liver-Dominant Hepatic Colorectal Cancer Metastases, and Cholangiocarcinoma Using Yttrium90 Microspheres: Eight-Year Single-Center Real-Life Experience.

Pellegrinelli J, Chevallier O, Manfredi S, Dygai-Cochet I, Tabouret-Viaud C, Nodari G, Ghiringhelli F, Riedinger JM, Popoff R, Vrigneaud JM, Cochet A, Aho S, Latournerie M, Loffroy R

Diagnostics (Basel). 2021 Jan 14;11(1):

The tumor microenvironment impairs Th1 IFNγ secretion through alternative splicing modifications of Irf1 pre-mRNA.

Bernard A, Hibos C, Richard C, Viltard E, Chevrier S, Lemoine S, Melin J, Humblin E, Mary R, Accogli T, Chalmin F, Bruchard M, Peixoto P, Hervouet E, Apetoh L, Ghiringhelli F, Vegran F, Boidot R

Cancer Immunol Res. 2021 Jan 8;:

New Artificial Intelligence Score and Immune Infiltrates as Prognostic Factors in Colorectal Cancer With Brain Metastases.

Randrian V, Desette A, Emambux S, Derangere V, Roussille P, Frouin E, Godet J, Karayan-Tapon L, Ghiringhelli F, Tougeron D

Front Immunol. 2021 ;12:750407

Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1.

Galland L, Le Page AL, Lecuelle J, Bibeau F, Oulkhouir Y, Derangère V, Truntzer C, Ghiringhelli F

Oncoimmunology. 2021 ;10(1):1957603

Immunodynamics of explanted human tumors for immuno-oncology.

Dubuisson A, Fahrner JE, Goubet AG, Terrisse S, Voisin N, Bayard C, Lofek S, Drubay D, Bredel D, Mouraud S, Susini S, Cogdill A, Rebuffet L, Ballot E, Jacquelot N, Thomas de Montpreville V, Casiraghi O, Radulescu C, Ferlicot S, Figueroa DJ, Yadavilli S, Waight JD, Ballas M, Hoos A, Condamine T, Parier B, Gaudillat C, Routy B, Ghiringhelli F, Derosa L, Breuskin I, Rouanne M, André F, Lebacle C, Baumert H, Wislez M, Fadel E, Cremer I, Albiges L, Geoerger B, Scoazec JY, Loriot Y, Kroemer G, Marabelle A, Bonvalet M, Zitvogel L

EMBO Mol Med. 2020 Dec 29;:e12850

Can the hyperthermia-mediated Heat Shock Factor (HSF) /Heat Shock Protein (HSP) 70 pathway dampen the cytokine storm during SARS-CoV-2 infection?

Rébé C, Ghiringhelli F, Garrido C

Br J Pharmacol. 2020 Dec 11;:

Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients.

Picard M, Yonekura S, Slowicka K, Petta I, Rauber C, Routy B, Richard C, Iebba V, Tidjani Alou M, Becharef S, Ly P, Pizzato E, Lehmann CHK, Amon L, Klein C, Opolon P, Gomperts Boneca I, Scoazec JY, Hollebecque A, Malka D, Ghiringhelli F, Dudziak D, Berx G, Vereecke L, van Loo G, Kroemer G, Zitvogel L, Roberti MP

Cell Death Differ. 2020 Dec 1;:

Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency.

Perrichet A, Ghiringhelli F, Rébé C

Cancers (Basel). 2020 Nov 27;12(12):

Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure.

Dolat M, Macaire P, Goirand F, Vincent J, Hennequin A, Palmier R, Bengrine-Lefevre L, Ghiringhelli F, Royer B, Schmitt A

Pharmaceuticals (Basel). 2020 Nov 23;13(11):

Influence of primary tumor location and resection on survival in metastatic colorectal cancer.

Tharin Z, Blanc J, Alaoui IC, Bertaut A, Ghiringhelli F

World J Gastrointest Oncol. 2020 Nov 15;12(11):1296-1310

Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers.

Medjebar S, Truntzer C, Perrichet A, Limagne E, Fumet JD, Richard C, Elkrief A, Routy B, Rébé C, Ghiringhelli F

Oncoimmunology. 2020 Oct 27;9(1):1836766

Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy.

Fumet JD, Limagne E, Thibaudin M, Ghiringhelli F

Cancers (Basel). 2020 Sep 16;12(9):

Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer.

Boustani J, Derangère V, Bertaut A, Adotevi O, Morgand V, Charon-Barra C, Ghiringhelli F, Mirjolet C

Cells. 2020 Sep 10;9(9):

Immunological features of coronavirus disease 2019 in patients with cancer.

Thibaudin M, Fumet JD, Bon M, Hampe L, Limagne E, Ghiringhelli F

Eur. J. Cancer. 2020 Sep 7;139:70-80

Ndiaye M, Rébé C, Pilot T, Ilie A, Ghiringhelli F

Rev. Neurol. (Paris). 2020 Sep;176S:S45

and impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response.

Laurent PA, Kownacka A, Boidot R, Richard C, Limagne E, Morgand V, Froidurot L, Bonin C, Aubignac L, Ghiringhelli F, Créhange G, Mirjolet C

Clin Transl Radiat Oncol. 2020 Sep;24:116-122

Tumor Infiltrating Lymphocytes Signature as a New Pan-Cancer Predictive Biomarker of Anti PD-1/PD-L1 Efficacy.

Ballot E, Ladoire S, Routy B, Truntzer C, Ghiringhelli F

Cancers (Basel). 2020 Aug 26;12(9):

Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage.

Fluckiger A, Daillère R, Sassi M, Sixt BS, Liu P, Loos F, Richard C, Rabu C, Alou MT, Goubet AG, Lemaitre F, Ferrere G, Derosa L, Duong CPM, Messaoudene M, Gagné A, Joubert P, De Sordi L, Debarbieux L, Simon S, Scarlata CM, Ayyoub M, Palermo B, Facciolo F, Boidot R, Wheeler R, Boneca IG, Sztupinszki Z, Papp K, Csabai I, Pasolli E, Segata N, Lopez-Otin C, Szallasi Z, Andre F, Iebba V, Quiniou V, Klatzmann D, Boukhalil J, Khelaifia S, Raoult D, Albiges L, Escudier B, Eggermont A, Mami-Chouaib F, Nistico P, Ghiringhelli F, Routy B, Labarrière N, Cattoir V, Kroemer G, Zitvogel L

Science. 2020 Aug 21;369(6506):936-942

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable a

Fumet JD, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E, Ghiringhelli F

BMC Cancer. 2020 Aug 10;20(1):748

Interleukin-1β and Cancer.

Rébé C, Ghiringhelli F

Cancers (Basel). 2020 Jul 4;12(7):

Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX.

Fumet JD, Vincent J, Bengrine L, Hennequin A, Granconato L, Palmier R, Ghiringhelli F

Anticancer Res.. 2020 Jul;40(7):4011-4015

Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma.

Niogret J, Limagne E, Thibaudin M, Blanc J, Bertaut A, Le Malicot K, Rinaldi Y, Caroli-Bosc FX, Audemar F, Nguyen S, Sarda C, Lombard-Bohas C, Locher C, Carreiro M, Legoux JL, Etienne PL, Baconnier M, Porneuf M, Aparicio T, Ghiringhelli F

Cancers (Basel). 2020 May 31;12(6):

Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.

Aarnink A, Fumet JD, Favier L, Truntzer C, Ghiringhelli F

J. Cancer Res. Clin. Oncol.. 2020 May 30;:

Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer.

Roberti MP, Yonekura S, Duong CPM, Picard M, Ferrere G, Tidjani Alou M, Rauber C, Iebba V, Lehmann CHK, Amon L, Dudziak D, Derosa L, Routy B, Flament C, Richard C, Daillère R, Fluckiger A, Van Seuningen I, Chamaillard M, Vincent A, Kourula S, Opolon P, Ly P, Pizzato E, Becharef S, Paillet J, Klein C, Marliot F, Pietrantonio F, Benoist S, Scoazec JY, Dartigues P, Hollebecque A, Malka D, Pagès F, Galon J, Gomperts Boneca I, Lepage P, Ryffel B, Raoult D, Eggermont A, Vanden Berghe T, Ghiringhelli F, Vandenabeele P, Kroemer G, Zitvogel L

Nat. Med.. 2020 May 25;:

Impact of G-CSF on FOLFIRINOX-induced neutropenia prevention: a population PK/PD approach.

Macaire P, Paris J, Vincent J, Ghiringhelli F, Bengrine-Lefevre L, Schmitt A

Br J Clin Pharmacol. 2020 May 9;:

Heat shock and HSP70 regulate 5-FU-mediated caspase-1 activation in myeloid-derived suppressor cells and tumor growth in mice.

Pilot T, Fratti A, Thinselin C, Perrichet A, Demontoux L, Limagne E, Derangère V, Ilie A, Ndiaye M, Jacquin E, Garrido C, Ghiringhelli F, Chalmin F, Rébé C

J Immunother Cancer. 2020 May;8(1):

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.

Kim S, Buecher B, André T, Jary M, Bidard FC, Ghiringhelli F, François É, Taieb J, Smith D, de la Fouchardière C, Desramé J, Samalin E, Parzy A, Baba-Hamed N, Bouché O, Tougeron D, Dahan L, El Hajbi F, Jacquin M, Rebucci-Peixoto M, Spehner L, Vendrely V, Vernerey D, Borg C

BMC Cancer. 2020 Apr 25;20(1):352

Red Wine Extract Disrupts Th17 Lymphocyte Differentiation in a Colorectal Cancer Context.

Chalons P, Courtaut F, Limagne E, Chalmin F, Cantos-Villar E, Richard T, Auger C, Chabert P, Schini-Kerth V, Ghiringhelli F, Aires V, Delmas D

Mol Nutr Food Res. 2020 Apr 18;:e1901286

Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts.

Fumet JD, Truntzer C, Yarchoan M, Ghiringhelli F

Eur. J. Cancer. 2020 Apr 9;131:40-50

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.

Aparicio T, Bennouna J, Le Malicot K, Boige V, Taieb J, Bouché O, Phelip JM, François E, Borel C, Faroux R, Dahan L, Bachet JB, Egreteau J, Kaminsky MC, Gornet JM, Cojocarasu O, Gasmi M, Guerin-Meyer V, Lepage C, Ghiringhelli F,

Br. J. Cancer. 2020 Feb 4;:

Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: Real-world data from multicentric cohorts in Canada and France.

Elkrief A, Richard C, Malo J, Cvetkovic L, Florescu M, Blais N, Tehfe M, Messaoudene M, Gagné A, Orain M, Medjebar S, Wan-Chow-Wah D, Joubert P, Labbé C, Ghiringhelli F, Routy B

J Geriatr Oncol. 2020 Jan 13;:

Implementation and use of whole exome sequencing in daily practice for metastatic solid cancer.

Réda M, Richard C, Bertaut A, Niogret J, Collot T, Fumet JD, Blanc J, Truntzer C, Desmoulins I, Ladoire S, Hennequin A, Favier L, Bengrine L, Vincent J, Hervieu A, Dusserre JG, Lepage C, Foucher P, Borg C, Albuisson J, Arnould L, Nambot S, Faivre L, Boidot R, Ghiringhelli F

EBioMedicine. 2020 Jan 7;51:102624

Cathepsin B Is Required for NLRP3 Inflammasome Activation in Macrophages, Through NLRP3 Interaction.

Chevriaux A, Pilot T, Derangère V, Simonin H, Martine P, Chalmin F, Ghiringhelli F, Rébé C

Front Cell Dev Biol. 2020 ;8:167

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma.

Kim S, Meurisse A, Spehner L, Stouvenot M, François E, Buecher B, André T, Samalin E, Jary M, Nguyen T, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, de la Fouchardiere C, Boulbair F, Lakkis Z, Klajer E, Jacquin M, Taieb J, Vendrely V, Vernerey D, Borg C

Ther Adv Med Oncol. 2020 ;12:1758835920975356

Immune Th17 lymphocytes play a critical role in the multiple beneficial properties of resveratrol.

Delmas D, Limagne E, Ghiringhelli F, Aires V

Food Chem. Toxicol.. 2019 Dec 26;:111091

Platinum Derivatives Effects on Anticancer Immune Response.

Rébé C, Demontoux L, Pilot T, Ghiringhelli F

Biomolecules. 2019 Dec 20;10(1):

Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study.

Reichling C, Taieb J, Derangere V, Klopfenstein Q, Le Malicot K, Gornet JM, Becheur H, Fein F, Cojocarasu O, Kaminsky MC, Lagasse JP, Luet D, Nguyen S, Etienne PL, Gasmi M, Vanoli A, Perrier H, Puig PL, Emile JF, Lepage C, Ghiringhelli F

Gut. 2019 Nov 28;:

Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study.

Walter T, Lepage C, Coriat R, Barbier E, Cadiot G, Caroli-Bosc FX, Aparicio T, Bouhier-Leporrier K, Hentic-Dhome O, Gay F, Dupont-Gossart AC, Duluc M, Lepere C, Lecomte T, Smith D, Petorin C, Di-Fiore F, Ghiringhelli F, Legoux JL, Guimbaud R, Baudin E, Lombard-Bohas C, de Baère T,

Eur. J. Cancer. 2019 Oct 31;123:92-100

Cleaved Caspase-3 transcriptionally regulates angiogenesis promoting chemotherapy resistance.

Bernard A, Chevrier S, Beltjens F, Dosset M, Viltard E, Lagrange A, Dérangère V, Oudot A, Ghiringhelli F, Collin B, Apetoh L, Feron O, Chen S, Arnould L, Végran F, Boidot R

Cancer Res.. 2019 Oct 14;:

Trifluridine/tipiracil plus oxaliplatin improves PD-1 blockade in colorectal cancer by inducing immunogenic cell death and depleting macrophages.

Limagne E, Thibaudin M, Nuttin L, Spill A, Dérangère V, Fumet JD, Amellal N, Peranzoni E, Cattan V, Ghiringhelli F

Cancer Immunol Res. 2019 Oct 14;:

Prognostic value of transcriptomic determination of tumour-infiltrating lymphocytes in localised breast cancer.

Truntzer C, Isambert N, Arnould L, Ladoire S, Ghiringhelli F

Eur. J. Cancer. 2019 Sep 6;120:97-106

STAT3, a Master Regulator of Anti-Tumor Immune Response.

Rébé C, Ghiringhelli F

Cancers (Basel). 2019 Aug 30;11(9):

Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study.

Basso V, Orry D, Fraisse J, Vincent J, Hennequin A, Bengrine L, Ghiringhelli F

World J Gastrointest Oncol. 2019 Aug 15;11(8):634-641

The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer.

Le Corre D, Ghazi A, Balogoun R, Pilati C, Aparicio T, Martin-Lannerée S, Marisa L, Djouadi F, Poindessous V, Crozet C, Emile JF, Mulot C, Le Malicot K, Boige V, Blons H, de Reynies A, Taieb J, Ghiringhelli F, Bennouna J, Launay JM, Laurent-Puig P, Mouillet-Richard S

EBioMedicine. 2019 Jul 31;:

Inactivation of proprotein convertases in T cells inhibits PD-1 expression and creates a favorable immune microenvironment in colorectal cancer.

Tomé M, Pappalardo A, Soulet F, López JJ, Olaizola J, Leger Y, Dubreuil M, Mouchard A, Fessart D, Delom F, Pitard V, Bechade D, Fonck M, Rosado JA, Ghiringhelli F, Déchanet-Merville J, Soubeyran I, Siegfried G, Evrard S, Khatib AM

Cancer Res.. 2019 Jul 29;:

Hypotonic stress enhances colon cancer cell death induced by platinum derivatives and immunologically improves anti-tumor efficacy of intraperitoneal chemotherapy.

Demontoux L, Derangère V, Pilot T, Thinselin C, Chevriaux A, Chalmin F, Bouyer F, Ghiringhelli F, Rébé C

Int. J. Cancer. 2019 Jul 25;:

Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study.

Ghiringhelli F, Vincent J, Bengrine L, Borg C, Jouve JL, Loffroy R, Guiu B, Blanc J, Bertaut A

J. Cancer Res. Clin. Oncol.. 2019 Jul 4;:

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance.

Pernot S, Terme M, Radosevic-Robin N, Castan F, Badoual C, Marcheteau E, Penault-Llorca F, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Baptiste Bachet J, Borg C, Boige V, Voron T, Stanbury T, Tartour E, Gourgou S, Malka D, Taieb J

Gastric Cancer. 2019 Jul 2;:

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.

Grapin M, Richard C, Limagne E, Boidot R, Morgand V, Bertaut A, Derangere V, Laurent PA, Thibaudin M, Fumet JD, Crehange G, Ghiringhelli F, Mirjolet C

J Immunother Cancer. 2019 Jun 25;7(1):160

Docosahexaenoic acid inhibits both NLRP3 inflammasome assembly and JNK-mediated mature IL-1β secretion in 5-fluorouracil-treated MDSC: implication in cancer treatment.

Dumont A, de Rosny C, Kieu TL, Perrey S, Berger H, Fluckiger A, Muller T, Pais de Barros JP, Pichon L, Hichami A, Thomas C, Rébé C, Ghiringhelli F, Rialland M

Cell Death Dis. 2019 Jun 19;10(7):485

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial.

Bidard FC, Kiavue N, Ychou M, Cabel L, Stern MH, Madic J, Saliou A, Rampanou A, Decraene C, Bouché O, Rivoire M, Ghiringhelli F, Francois E, Guimbaud R, Mineur L, Khemissa-Akouz F, Mazard T, Moussata D, Proudhon C, Pierga JY, Stanbury T, Thézenas S, Mariani P

Cells. 2019 May 28;8(6):

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J

Eur. J. Cancer. 2019 May 23;115:97-106

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.

Dohan A, Gallix B, Guiu B, Le Malicot K, Reinhold C, Soyer P, Bennouna J, Ghiringhelli F, Barbier E, Boige V, Taieb J, Bouché O, François E, Phelip JM, Borel C, Faroux R, Seitz JF, Jacquot S, Ben Abdelghani M, Khemissa-Akouz F, Genet D, Jouve JL, Rinaldi Y, Desseigne F, Texereau P, Suc E, Lepage C, Aparico T, Hoeffel C,

Gut. 2019 May 17;:

Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.

Borg C, Mantion G, Boudghène F, Mornex F, Ghiringhelli F, Adenis A, Azria D, Balosso J, Ben Abdelghani M, Bachet JB, Vendrely V, François Y, Conroy T, Rio E, Roullet B, Spaëth D, Quero L, Lakkis Z, Coudert M, Ionescu-Goga M, Tanang A, André T

Clin Colorectal Cancer. 2019 May 3;:

Factors influencing patient's perception of long-term treatment with low-molecular-weight heparins for cancer-associated thrombosis: an updated analysis of TROPIQUE, a prospective observational study.

Debourdeau P, Arvers P, Hij A, Bennani H, Desauw C, Falvo N, Ghiringhelli F, Hamadé A, Vedrine L, Farge D

Support Care Cancer. 2019 May 1;:

Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF2.

Cherfils-Vicini J, Iltis C, Cervera L, Pisano S, Croce O, Sadouni N, Győrffy B, Collet R, Renault VM, Rey-Millet M, Leonetti C, Zizza P, Allain F, Ghiringhelli F, Soubeiran N, Shkreli M, Vivier E, Biroccio A, Gilson E

EMBO J.. 2019 Apr 18;:

Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase 2 study.

Toulmonde M, Bellera CA, Blay JY, Bouche O, Mir O, Penel N, Isambert N, Duffaud F, Esnaud T, Boidot R, Geneste D, Ghiringhelli F, Lucchesi C, Le Loarer F, Italiano A

Clin. Cancer Res.. 2019 Apr 12;:

Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic Colorectal Cancer: Case Series and Rationale.

Ledys F, Derangère V, Réda M, Guion JF, Milliex R, Roux V, Limagne E, Arnould L, Bengrine L, Ghiringhelli F, Rébé C

Adv Ther. 2019 Apr 12;:

T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants.

Messaoudene M, Mourikis TP, Michels J, Fu Y, Bonvalet M, Lacroix-Trikki M, Routy B, Fluckiger A, Rusakiewicz S, Roberti MP, Cotteret S, Flament C, Poirier-Colame V, Jacquelot N, Ghiringhelli F, Caignard A, Eggermont AMM, Kroemer G, Marabelle A, Arnedos M, Vicier C, Dogan S, Jaulin F, Sammut SJ, Cope W, Caldas C, Delaloge S, McGranahan N, André F, Zitvogel L

Ann. Oncol.. 2019 Mar 29;:

Cell lines and immune classification of glioblastoma define patient's prognosis.

Klopfenstein Q, Truntzer C, Vincent J, Ghiringhelli F

Br. J. Cancer. 2019 Mar 22;:

HSP70 is a negative regulator of NLRP3 inflammasome activation.

Martine P, Chevriaux A, Derangère V, Apetoh L, Garrido C, Ghiringhelli F, Rébé C

Cell Death Dis. 2019 Mar 15;10(4):256

Therapeutic drug monitoring as a tool to optimize 5-FU-based chemotherapy in gastrointestinal cancer patients older than 75 years.

Macaire P, Morawska K, Vincent J, Quipourt V, Marilier S, Ghiringhelli F, Bengrine-Lefevre L, Schmitt A

Eur. J. Cancer. 2019 Mar 5;111:116-125

Partial splenic embolization with Glubran2/Lipiodol mixture for oncological patients with hypersplenism-related thrombocytopenia requiring systemic chemotherapy.

Loffroy R, Falvo N, Nakaï M, Pescatori L, Aho-Gléglé S, Gehin S, Berthod PE, Né R, Vincent J, Ghiringhelli F, Midulla M, Chevallier O

Quant Imaging Med Surg. 2019 Mar;9(3):409-417

Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer.

Devaux M, Gerard L, Richard C, Bengrine-Lefevre L, Vincent J, Schmitt A, Ghiringhelli F

World J Clin Oncol. 2019 Feb 24;10(2):75-85

Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS).

Adenis A, Bennouna J, Etienne PL, Bogart E, Francois E, Galais MP, Ben Abdelghani M, Michel P, Metges JP, Dahan L, Conroy T, Ghiringhelli F, Drouillard A, El Hajbi F, Samalin E, Hiret S, Delaine-Clisant S, Mariette C, Penel N, Piessen G, Le Deley MC

Eur. J. Cancer. 2019 Feb 21;111:12-20

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer.

Kaderbhaï C, Tharin Z, Ghiringhelli F

Cancers (Basel). 2019 Feb 10;11(2):

Deciphering the Roles of Innate Lymphoid Cells in Cancer.

Bruchard M, Ghiringhelli F

Front Immunol. 2019 ;10:656

Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?

Ghiringhelli F, Fumet JD

Front Immunol. 2019 ;10:1816

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients.

Limagne E, Richard C, Thibaudin M, Fumet JD, Truntzer C, Lagrange A, Favier L, Coudert B, Ghiringhelli F

Oncoimmunology. 2019 ;8(4):e1564505

Ghiringhelli F

Bull Cancer. 2018 Dec;105 Suppl 1:S101-S112

Genomic biomarker of checkpoint efficacy, highways for precision medicine in lung cancer.

Ghiringhelli F, Truntzer C

Oncotarget. 2018 Nov 27;9(93):36547-36548

Regulation of T cell antitumor immune response by tumor induced metabolic stress.

Chalmin F, Bruchard M, Vegran F, Ghiringhelli F

Cell Stress. 2018 Nov 27;3(1):9-18

RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer.

Ledys F, Klopfenstein Q, Truntzer C, Arnould L, Vincent J, Bengrine L, Remark R, Boidot R, Ladoire S, Ghiringhelli F, Derangere V

J Immunother Cancer. 2018 Nov 19;6(1):123

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.

Bennouna J, Hiret S, Bertaut A, Bouché O, Deplanque G, Borel C, François E, Conroy T, Ghiringhelli F, des Guetz G, Seitz JF, Artru P, Hebbar M, Stanbury T, Denis MG, Adenis A, Borg C

JAMA Oncol. 2018 Oct 25;:

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.

Fumet JD, Richard C, Ledys F, Klopfenstein Q, Joubert P, Routy B, Truntzer C, Gagné A, Hamel MA, Guimaraes CF, Coudert B, Arnould L, Favier L, Lagrange A, Ladoire S, Saintigny P, Ortiz-Cuaran S, Perol M, Foucher P, Hofman P, Ilie M, Chevrier S, Boidot R, Derangere V, Ghiringhelli F

Br. J. Cancer. 2018 Oct 15;:

Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors.

Collot T, Fumet JD, Klopfenstein Q, Vincent J, Bengrine L, Ghiringhelli F

Anticancer Res.. 2018 Oct;38(10):5963-5968

The combination of trifluridine/tipiracil and oxaliplatin induces immunogenic cell death in microsatellite stable colorectal cancer.

Ghiringhelli F, Limagne E, Thibaudin M, Nuttin L, Spill A, Derangere V, Cattan V, Peranzoni E, Amellal N

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii186

UCGI 28 Panirinox: A randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis.

Mazard T, Ghiringhelli F, Mollevi C, Assenat E, Gavoille C, Smith D, Pezzella V, Meddeb R, Pastor B, Ychou M, Thierry AR

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii204

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.

Brandes AA, Gil-Gil M, Saran F, Carpentier AF, Nowak AK, Mason W, Zagonel V, Dubois F, Finocchiaro G, Fountzilas G, Cernea DM, Chinot O, Anghel R, Ghiringhelli F, Beauchesne P, Lombardi G, Franceschi E, Makrutzki M, Mpofu C, Urban HJ, Pichler J

Oncologist. 2018 Sep 28;:

FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer.

Carola C, Ghiringhelli F, Kim S, André T, Barlet J, Bengrine-Lefevre L, Marijon H, Garcia-Larnicol ML, Borg C, Dainese L, Steuer N, Richa H, Benetkiewicz M, Larsen AK, de Gramont A, Chibaudel B

World J Clin Oncol. 2018 Sep 14;9(5):110-118

Exome analysis reveals genomic markers associated with better efficacy of nivolumab in lung cancer patients.

Richard C, Fumet JD, Chevrier S, Derangère V, Ledys F, Lagrange A, Favier L, Coudert B, Arnould L, Truntzer C, Boidot R, Ghiringhelli F

Clin. Cancer Res.. 2018 Aug 28;:

Secondary findings from whole-exome/genome sequencing evaluating stakeholder perspectives. A review of the literature.

Delanne J, Nambot S, Chassagne A, Putois O, Pelissier A, Peyron C, Gautier E, Thevenon J, Cretin E, Bruel AL, Goussot V, Ghiringhelli F, Boidot R, Tran-Mau-Them F, Philippe C, Vitobello A, Demougeot L, Vernin C, Lapointe AS, Bardou M, Luu M, Binquet C, Lejeune C, Joly L, Juif C, Baurand A, Sawka C, Bertolone G, Duffourd Y, Sanlaville D, Pujol P, Geneviève D, Houdayer F, Thauvin-Robinet C, Faivre L

Eur J Med Genet. 2018 Aug 27;:

Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients.

Manfroi B, Moreaux J, Righini C, Ghiringhelli F, Sturm N, Huard B

Blood Cancer J. 2018 Jul 5;8(7):66

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C

Lancet Oncol.. 2018 Jul 2;:

Identification of resources and skills developed by partners of patients with advanced colon cancer: a qualitative study.

Meunier-Beillard N, Ponthier N, Lepage C, Gagnaire A, Gheringuelli F, Bengrine L, Boudrant A, Rambach L, Quipourt V, Devilliers H, Lejeune C

Support Care Cancer. 2018 Jun 5;:

Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma.

Aarnink A, Richard C, Truntzer C, Vincent J, Bengrine L, Vienot A, Borg C, Ghiringhelli F

Oncotarget. 2018 May 22;9(39):25617-25629

[Novel strategy in oncoimmunology].

Ghiringhelli F

Bull Cancer. 2018 Apr 25;:

amplification induces sensitivity to anti therapy in pancreatic acinar cell carcinoma.

Richard C, Niogret J, Boidot R, Ghiringhelli F

World J Gastrointest Oncol. 2018 Apr 15;10(4):103-107

3 Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

André T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egreteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J,

J. Clin. Oncol.. 2018 Apr 5;:JCO2017760355

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

Aparicio T, Ghiringhelli F, Boige V, Le Malicot K, Taieb J, Bouché O, Phelip JM, François E, Borel C, Faroux R, Dahan L, Jacquot S, Genet D, Khemissa F, Suc E, Desseigne F, Texereau P, Lepage C, Bennouna J,

J. Clin. Oncol.. 2018 Mar 1;36(7):674-681

Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial.

Fumet JD, Bertaut A, Bengrine L, Lapierre P, Vincent J, Ghiringhelli F, Falvo N

Oncotarget. 2018 Feb 27;9(16):12599-12608

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).

Reyes-Botero G, Cartalat-Carel S, Chinot OL, Barrie M, Taillandier L, Beauchesne P, Catry-Thomas I, Barrière J, Guillamo JS, Fabbro M, Frappaz D, Benouaich-Amiel A, Le Rhun E, Campello C, Tennevet I, Ghiringhelli F, Tanguy ML, Mokhtari K, Honnorat J, Delattre JY

Oncologist. 2018 Feb 22;:

5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer.

Morawska K, Goirand F, Marceau L, Devaux M, Cueff A, Bertaut A, Vincent J, Bengrine-Lefevre L, Ghiringhelli F, Schmitt A

Oncotarget. 2018 Feb 20;9(14):11559-11571

Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance.

Cotte AK, Aires V, Fredon M, Limagne E, Derangère V, Thibaudin M, Humblin E, Scagliarini A, de Barros JP, Hillon P, Ghiringhelli F, Delmas D

Nat Commun. 2018 01 22;9(1):322

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L

Science. 2018 Jan 5;359(6371):91-97

Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study.

Isambert N, Hervieu A, Rébé C, Hennequin A, Borg C, Zanetta S, Chevriaux A, Richard C, Derangère V, Limagne E, Blanc J, Bertaut A, Ghiringhelli F

Oncoimmunology. 2018 ;7(9):e1474319

LPCAT2 controls chemoresistance in colorectal cancer.

Cotte AK, Aires V, Ghiringhelli F, Delmas D

Mol Cell Oncol. 2018 ;5(3):e1448245

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.

Dosset M, Vargas TR, Lagrange A, Boidot R, Végran F, Roussey A, Chalmin F, Dondaine L, Paul C, Marie-Joseph EL, Martin F, Ryffel B, Borg C, Adotévi O, Ghiringhelli F, Apetoh L

Oncoimmunology. 2018 ;7(6):e1433981

Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer.

Fumet JD, Isambert N, Hervieu A, Zanetta S, Guion JF, Hennequin A, Rederstorff E, Bertaut A, Ghiringhelli F

ESMO Open. 2018 ;3(4):e000375

The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.

Marisa L, Svrcek M, Collura A, Becht E, Cervera P, Wanherdrick K, Buhard O, Goloudina A, Jonchère V, Selves J, Milano G, Guenot D, Cohen R, Colas C, Laurent-Puig P, Olschwang S, Lefèvre JH, Parc Y, Boige V, Lepage C, André T, Fléjou JF, Dérangère V, Ghiringhelli F, de Reynies A, Duval A

J. Natl. Cancer Inst.. 2018 Jan 1;110(1):

Transcriptional Programs Underlying Cd4 T Cell Differentiation and Functions.

Chalmin F, Humblin E, Ghiringhelli F, Végran F

Int Rev Cell Mol Biol. 2018 ;341:1-61

Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC study.

Mirjolet C, Charon-Barra C, Ladoire S, Arbez-Gindre F, Bertaut A, Ghiringhelli F, Leroux A, Peiffert D, Borg C, Bosset JF, Créhange G

Oncoimmunology. 2018 ;7(3):e1396402

[Combinations of chemotherapy or radiotherapy with checkpoint inhibitors].

Ghiringhelli F

Biol Aujourdhui. 2018 ;212(3-4):77-79

IRF8-dependent molecular complexes control the Th9 transcriptional program.

Humblin E, Thibaudin M, Chalmin F, Derangère V, Limagne E, Richard C, Flavell RA, Chevrier S, Ladoire S, Berger H, Boidot R, Apetoh L, Végran F, Ghiringhelli F

Nat Commun. 2017 Dec 12;8(1):2085

Protective effects of polyphenol-rich infusions from carob (Ceratonia siliqua) leaves and cladodes of Opuntia ficus-indica against inflammation associated with diet-induced obesity and DSS-induced colitis in Swiss mice.

Aboura I, Nani A, Belarbi M, Murtaza B, Fluckiger A, Dumont A, Benammar C, Tounsi MS, Ghiringhelli F, Rialland M, Khan NA, Hichami A

Biomed. Pharmacother.. 2017 Dec;96:1022-1035

Selective degradation of PU.1 during autophagy represses the differentiation and antitumour activity of TH9 cells.

Rivera Vargas T, Cai Z, Shen Y, Dosset M, Benoit-Lizon I, Martin T, Roussey A, Flavell RA, Ghiringhelli F, Apetoh L

Nat Commun. 2017 Sep;8(1):559

Antibiotic Use Does Not Appear to Influence Response to Nivolumab.

Kaderbhai C, Richard C, Fumet JD, Aarnink A, Foucher P, Coudert B, Favier L, Lagrange A, Limagne E, Boidot R, Ghiringhelli F

Anticancer Res.. 2017 06;37(6):3195-3200

Precision medicine in breast cancer: reality or utopia?

Bettaieb A, Paul C, Plenchette S, Shan J, Chouchane L, Ghiringhelli F

J Transl Med. 2017 Jun;15(1):139

Trifluridine/Tipiracil combined to oxaliplatin sensitizes microsatellite stable colorectal cancer to anti-PD-1 blockade.

Limagne E, Nuttin L, Spill A, Thibaudin M, Derangere V, Cattan V, Bruno A, Amellal N, Ghiringhelli F

Ann. Oncol.. 2017 Jun;28 Suppl 3:iii90

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.

Toulmonde M, Penel N, Adam J, Chevreau C, Blay JY, Le Cesne A, Bompas E, Piperno-Neumann S, Cousin S, Grellety T, Ryckewaert T, Bessede A, Ghiringhelli F, Pulido M, Italiano A

JAMA Oncol. 2017 Jun;:

Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.

Pernot S, Badoual C, Terme M, Castan F, Cazes A, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Bachet JB, Borg C, Ducreux M, Marcheteau E, Stanbury T, Gourgou S, Malka D, Taieb J

Eur. J. Cancer. 2017 Apr;79:15-22

Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation.

Limagne E, Thibaudin M, Euvrard R, Berger H, Chalons P, Végan F, Humblin E, Boidot R, Rébé C, Derangère V, Ladoire S, Apetoh L, Delmas D, Ghiringhelli F

Cell Rep. 2017 Apr;19(4):746-759

Implications of excess weight in the cardiotoxicity of anthracyclines and trastuzumab in breast cancer.

Guenancia C, Ladoire S, Ghiringelli F, Rochette L, Vergely C, Cottin Y

Arch Cardiovasc Dis. 2017 Feb;110(2):69-71

[The anti-tumor immune response in breast cancer: Update and therapeutic perspectives].

Ladoire S, Derangère V, Arnould L, Thibaudin M, Coudert B, Lorgis V, Desmoulins I, Chaix M, Fumoleau P, Ghiringhelli F

Ann Pathol. 2017 Feb;37(1):133-141

Alteration in Taste Perception in Cancer: Causes and Strategies of Treatment.

Murtaza B, Hichami A, Khan AS, Ghiringhelli F, Khan NA

Front Physiol. 2017 ;8:134

Correction: Phenolic extract from oleaster (Olea europaea var. Sylvestris) leaves reduces colon cancer growth and induces caspase-dependent apoptosis in colon cancer cells via the mitochondrial apoptotic pathway.

Zeriouh W, Nani A, Belarbi M, Dumont A, de Rosny C, Aboura I, Ghanemi FZ, Murtaza B, Patoli D, Thomas C, Apetoh L, Rébé C, Delmas D, Khan NA, Ghiringhelli F, Rialland M, Hichami A

PLoS ONE. 2017 ;12(4):e0176574

Immune classifications with cytotoxic CD8(+) and Th17 infiltrates are predictors of clinical prognosis in glioblastoma.

Madkouri R, Kaderbhai CG, Bertaut A, Truntzer C, Vincent J, Aubriot-Lorton MH, Farah W, Limagne E, Ladoire S, Boidot R, Derangère V, Ghiringhelli F

Oncoimmunology. 2017 ;6(6):e1321186

Phenolic extract from oleaster (Olea europaea var. Sylvestris) leaves reduces colon cancer growth and induces caspase-dependent apoptosis in colon cancer cells via the mitochondrial apoptotic pathway.

Zeriouh W, Nani A, Belarbi M, Dumont A, de Rosny C, Aboura I, Ghanemi FZ, Murtaza B, Patoli D, Thomas C, Apetoh L, Rébé C, Delmas D, Akhtar Khan N, Ghiringhelli F, Rialland M, Hichami A

PLoS ONE. 2017 ;12(2):e0170823

Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer.

Kaderbhai CG, Richard C, Fumet JD, Aarnink A, Ortiz-Cuaran S, Pérol M, Foucher P, Coudert B, Favier L, Lagrange A, Limagne E, Boidot R, Ladoire S, Poudenx M, Ilie M, Hofman P, Saintigny P, Ghiringhelli F

Oncoimmunology. 2017 ;6(9):e1339856

TH9 cells in anti-tumor immunity.

Rivera Vargas T, Humblin E, Végran F, Ghiringhelli F, Apetoh L

Semin Immunopathol. 2017 Jan;39(1):39-46

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?

Eliade M, Skrzypski J, Baurand A, Jacquot C, Bertolone G, Loustalot C, Coutant C, Guy F, Fumoleau P, Duffourd Y, Arnould L, Delignette A, Padéano MM, Lepage C, Raichon-Patru G, Boudrant A, Bône-Lépinoy MC, Villing AL, Charpin A, Peignaux K, Chevrier S, Vegran F, Ghiringhelli F, Boidot R, Sevenet N, Lizard S, Faivre L

Oncotarget. 2017 Jan;8(2):1957-1971

Transcription Factor Binding Studies in CD4+ T Cells: siRNA Transfection, Chromatin Immunoprecipitation, and Liquid Luminescent DNA Precipitation Assay.

Humblin E, Ghiringhelli F, Végran F

Methods Mol. Biol.. 2017 ;1585:167-177

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.

Ghiringhelli F, Richard C, Chevrier S, Végran F, Boidot R

World J. Gastroenterol.. 2016 Dec;22(48):10680-10686

Peroxisome proliferator-activated receptor alpha deficiency impairs regulatory T cell functions: Possible application in the inhibition of melanoma tumor growth in mice.

Hichami A, Yessoufou A, Ghiringhelli F, Salvadori F, Moutairou K, Zwetyenga N, Khan NA

Biochimie. 2016 Dec;131:1-10

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy.

Guion-Dusserre JF, Bertaut A, Ghiringhelli F, Vincent J, Quipourt V, Marilier S, Tharin Z, Bengrine-Lefevre L

World J. Gastroenterol.. 2016 Nov;22(42):9378-9386

Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score.

Jary M, Lecomte T, Bouché O, Kim S, Dobi E, Queiroz L, Ghiringhelli F, Etienne H, Léger J, Godet Y, Balland J, Lakkis Z, Adotevi O, Bonnetain F, Borg C, Vernerey D

Int. J. Cancer. 2016 Nov;139(10):2325-35

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma.

Bertaut A, Truntzer C, Madkouri R, Kaderbhai CG, Derangère V, Vincent J, Chauffert B, Aubriot-Lorton MH, Farah W, Mourier KL, Boidot R, Ghiringhelli F

Oncotarget. 2016 Oct;7(43):70948-70958

Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen.

Limagne E, Euvrard R, Thibaudin M, Rébé C, Derangère V, Chevriaux A, Boidot R, Végran F, Bonnefoy N, Vincent J, Bengrine-Lefevre L, Ladoire S, Delmas D, Apetoh L, Ghiringhelli F

Cancer Res.. 2016 Sep;76(18):5241-52

Inhibition of colon cancer growth by docosahexaenoic acid involves autocrine production of TNFα.

Fluckiger A, Dumont A, Derangère V, Rébé C, de Rosny C, Causse S, Thomas C, Apetoh L, Hichami A, Ghiringhelli F, Rialland M

Oncogene. 2016 Sep;35(35):4611-22

Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis.

Guenancia C, Lefebvre A, Cardinale D, Yu AF, Ladoire S, Ghiringhelli F, Zeller M, Rochette L, Cottin Y, Vergely C

J. Clin. Oncol.. 2016 Sep;34(26):3157-65

Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.

Paquette B, Vernerey D, Chauffert B, Dabakuyo S, Feuvret L, Taillandier L, Frappaz D, Taillia H, Schott R, Ducray F, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O, Anota A, Bonnetain F

Cancer Med. 2016 Aug;5(8):1753-64

Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate.

Ladoire S, Senovilla L, Enot D, Ghiringhelli F, Poirier-Colame V, Chaba K, Erdag G, Schaefer JT, Deacon DH, Zitvogel L, Slingluff CL, Kroemer G

Oncoimmunology. 2016 Jun;5(6):e1160193

The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer.

Ladoire S, Enot D, Senovilla L, Ghiringhelli F, Poirier-Colame V, Chaba K, Semeraro M, Chaix M, Penault-Llorca F, Arnould L, Poillot ML, Arveux P, Delaloge S, Andre F, Zitvogel L, Kroemer G

Autophagy. 2016 May;12(5):864-75

Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer.

Kaderbhai CG, Boidot R, Beltjens F, Chevrier S, Arnould L, Favier L, Lagrange A, Coudert B, Ghiringhelli F

Oncotarget. 2016 Apr;7(17):24860-70

[Th9 cells: a new population of helper T cells].

Vegran F, Martin F, Apetoh L, Ghiringhelli F

Med Sci (Paris). 2016 Apr;32(4):387-93

Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer.

Gobbo J, Marcion G, Cordonnier M, Dias AM, Pernet N, Hammann A, Richaud S, Mjahed H, Isambert N, Clausse V, Rébé C, Bertaut A, Goussot V, Lirussi F, Ghiringhelli F, de Thonel A, Fumoleau P, Seigneuric R, Garrido C

J. Natl. Cancer Inst.. 2016 Mar;108(3):

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?

Derangère V, Fumet JD, Boidot R, Bengrine L, Limagne E, Chevriaux A, Vincent J, Ladoire S, Apetoh L, Rébé C, Ghiringhelli F

Oncotarget. 2016 Feb;7(8):9309-21

Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients.

Hennequin A, Derangère V, Boidot R, Apetoh L, Vincent J, Orry D, Fraisse J, Causeret S, Martin F, Arnould L, Beltjens F, Ghiringhelli F, Ladoire S

Oncoimmunology. 2016 Feb;5(2):e1054598

First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control.

Kotecki N, Hiret S, Etienne PL, Penel N, Tresch E, François E, Galais MP, Ben Abdelghani M, Michel P, Dahan L, Ghiringelli F, Bedenne L, Samalin E, Piessen G, Bennouna J, Peugniez C, El Hajbi F, Clisant S, Kramar A, Mariette C, Adenis A

Oncology. 2016 ;90(2):88-96

Effects of polyphenols and lipids from Pennisetum glaucum grains on T-cell activation: modulation of Ca(2+) and ERK1/ERK2 signaling.

Nani A, Belarbi M, Ksouri-Megdiche W, Abdoul-Azize S, Benammar C, Ghiringhelli F, Hichami A, Khan NA

BMC Complement Altern Med. 2015 Dec;15:426

[An IgG4-related pancreatitis mimicking an adenocarcinoma: A case report].

Courcet E, Beltjens F, Charon-Barra C, Guy F, Orry D, Ghiringhelli F, Arnould L

Ann Pathol. 2015 Dec;35(6):511-4

HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report.

Boidot R, Chevrier S, Julie V, Ladoire S, Ghiringhelli F

Int J Colorectal Dis. 2015 Nov 12.

Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer.

Ladoire S, Penault-Llorca F, Senovilla L, Dalban C, Enot D, Locher C, Prada N, Poirier-Colame V, Chaba K, Arnould L, Ghiringhelli F, Fumoleau P, Spielmann M, Delaloge S, Poillot ML, Arveux P, Goubar A, Andre F, Zitvogel L, Kroemer G

Autophagy. 2015 Oct 3;11(10):1878-90

Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients.

Ghiringhelli F, Vincent J, Beltjens F, Bengrine L, Ladoire S

Invest New Drugs. 2015 Oct 22.

Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas.

Alentorn A, Dehais C, Ducray F, Carpentier C, Mokhtari K, Figarella-Branger D, Chinot O, Cohen-Moyal E, Ramirez C, Loiseau H, Elouahdani-Hamdi S, Beauchesne P, Langlois O, Desenclos C, Guillamo JS, Dam-Hieu P, Ghiringhelli F, Colin P, Godard J, Parker F, Dhermain F, Carpentier AF, Frenel JS, Menei P, Bauchet L, Faillot T, Fesneau M, Fontaine D, Motuo-Fotso MJ, Vauleon E, Gaultier C, Le Guerinel C, Gueye EM, Noel G, Desse N, Durando X, Barrascout E, Wager M, Ricard D, Carpiuc I, Delattre JY, Idbaih A

Neurology. 2015 Sep 18. pii: 10.1212/WNL.0000000000002014.

Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies?

Rebe C, Ghiringhelli F

Future Oncol. 2015 Sep 17.

Liver X receptor ligand cytotoxicity in colon cancer cells and not in normal colon epithelial cells depends on LXRbeta subcellular localization.

Courtaut F, Derangere V, Chevriaux A, Ladoire S, Cotte AK, Arnould L, Boidot R, Rialland M, Ghiringhelli F, Rebe C

Oncotarget. 2015 Sep 29;6(29):26651-62

Stress-Induced Depressive Behaviors Require a Functional NLRP3 Inflammasome.

Alcocer-Gomez E, Ulecia-Moron C, Marin-Aguilar F, Rybkina T, Casas-Barquero N, Ruiz-Cabello J, Ryffel B, Apetoh L, Ghiringhelli F, Bullon P, Sanchez-Alcazar JA, Carrion AM, Cordero MD

Mol Neurobiol. 2015 Sep 11.

Transcriptome analysis of TH2 CD4(+) T cells differentiated from wild-type and NLRP3KO mice.

Bruchard M, Boidot R, Ghiringhelli F, Vegran F

Genom Data. 2015 Jul 9;5:314-5

Acute and delayed toxicity of gemcitabine administered during isolated lung perfusion: a preclinical dose-escalation study in pigs.

Pagès PB, Derangere V, Bouchot O, Magnin G, Charon-Barra C, Lokiec F, Ghiringhelli F, Bernard A

Eur J Cardiothorac Surg. 2015 Aug;48(2):228-35

The receptor NLRP3 is a transcriptional regulator of TH2 differentiation.

Bruchard M, Rebe C, Derangere V, Togbe D, Ryffel B, Boidot R, Humblin E, Hamman A, Chalmin F, Berger H, Chevriaux A, Limagne E, Apetoh L, Vegran F, Ghiringhelli F

Nat Immunol. 2015 Aug;16(8):859-70

AMPK phosphorylation modulates pain by activation of NLRP3-inflammasome.

Bullon P, Alcocer-Gomez E, Carrion AM, Garrido-Maraver J, Marin-Aguilar F, Roman-Malo L, Ruiz-Cabello J, Culic O, Ryffel B, Apetoh L, Ghiringhelli F, Battino M, Sanchez-Alcazar JA, Cordero MD

Antioxid Redox Signal. 2015 Jul 1.

Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?

Apetoh L, Ladoire S, Coukos G, Ghiringhelli F

Ann Oncol. 2015 Apr 28. pii: mdv209.

The role of telomeres in predicting individual radiosensitivity of patients with cancer in the era of personalized radiotherapy.

Mirjolet C, Boidot R, Saliques S, Ghiringhelli F, Maingon P, Crehange G

Cancer Treat Rev. 2015 Apr;41(4):354-60

UGT1A1 genotype and irinotecan therapy: General review and implementation in routine practice.

Etienne-Grimaldi MC, Boyer JC, Thomas F, Quaranta S, Picard N, Loriot MA, Narjoz C, Poncet D, Gagnieu MC, Ged C, Broly F, Morvan VL, Bouquie R, Gaub MP, Philibert L, Ghiringhelli F, Le Guellec C

Fundam Clin Pharmacol. 2015 Mar 27

Caspase-1 activation by NLRP3 inflammasome dampens IL-33-dependent house dust mite-induced allergic lung inflammation.

Madouri F, Guillou N, Fauconnier L, Marchiol T, Rouxel N, Chenuet P, Ledru A, Apetoh L, Ghiringhelli F, Chamaillard M, Zheng SG, Trovero F, Quesniaux VF, Ryffel B, Togbe D

J Mol Cell Biol. 2015 Feb 24. pii: mjv012.

FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.

Guion-Dusserre JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F

World J Gastroenterol. 2015 Feb 21;21(7):2096-101

Gut microbiome and anticancer immune response: really hot Sh*t!

Viaud S, Daillere R, Boneca IG, Lepage P, Langella P, Chamaillard M, Pittet MJ, Ghiringhelli F, Trinchieri G, Goldszmid R, Zitvogel L

Cell Death Differ. 2015 Feb;22(2):199-214

Th9 cells: a novel CD4 T-cell subset in the immune war against cancer.

Vegran F, Apetoh L, Ghiringhelli F

Cancer Res. 2015 Feb 1;75(3):475-9

FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9 - FFCD 0802).

Aparicio T, Linot B, Le Malicot K, Bouche O, Boige V, Francois E, Ghiringhelli F, Legoux JL, Abdelghani MB, Phelip JM, Faroux R, Dahan L, Taieb J, Bedenne L

Dig Liver Dis. 2015 Jan 20. pii: S1590-8658(15)00168-1

High pressure does not counterbalance the advantages of open techniques over closed techniques during heated intraperitoneal chemotherapy with oxaliplatin.

Facy O, Combier C, Poussier M, Magnin G, Ladoire S, Ghiringhelli F, Chauffert B, Rat P, Ortega-Deballon P

Surgery. 2015 Jan;157(1):72-8

Prognostic Value of Angiopoietin-2 for death risk stratification in Patients with Metastatic Colorectal Carcinoma.

Jary M, Vernerey D, Lecomte T, Dobi E, Ghiringhelli F, Monnien F, Godet Y, Kim S, Bouche O, Fratte S, Goncalves A, Leger J, Queiroz L, Adotevi O, Bonnetain F, Borg C

Cancer Epidemiol Biomarkers Prev. 2015 Jan 12. pii: cebp.1059.2014.

The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas.

Kim S, Fiteni F, Paget-Bailly S, Ghiringhelli F, Lakkis Z, Jary M, Fein F, Bonnetain F, Mariette C, Borg C

J Hematol Oncol. 2015 May 15;8(1):52

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fucikova J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jager D, Kalinski P, Karre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautes-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G

Oncotarget. 2014 Dec 30;5(24):12472-508.

Liver X receptor beta activation induces pyroptosis of human and murine colon cancer cells.

Derangere V, Chevriaux A, Courtaut F, Bruchard M, Berger H, Chalmin F, Causse SZ, Limagne E, Vegran F, Ladoire S, Simon B, Boireau W, Hichami A, Apetoh L, Mignot G, Ghiringhelli F, Rebe C

Cell Death Differ. 2014 Dec;21(12):1914-24

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buque A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fucikova J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct.

Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: a French population-based study.

Ghiringhelli F, Hennequin A, Drouillard A, Lepage C, Faivre J, Bouvier AM

Dig Liver Dis. 2014 Sep;46(9):854-8

Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations.

Chevrier S, Arnould L, Ghiringhelli F, Coudert B, Fumoleau P, Boidot R

Int J Oncol. 2014 Sep;45(3):1167-74

Enhancing the Anticancer Effects of 5-Fluorouracil: Current Challenges and Future Perspectives.

Ghiringhelli F, Apetoh L

Biomed J. 2014 Aug 28

Harnessing the intestinal microbiome for optimal therapeutic immunomodulation.

Viaud S, Daillere R, Boneca IG, Lepage P, Pittet MJ, Ghiringhelli F, Trinchieri G, Goldszmid R, Zitvogel L

Cancer Res. 2014 Aug 15;74(16):4217-21

The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells.

Vegran F, Berger H, Boidot R, Mignot G, Bruchard M, Dosset M, Chalmin F, Rebe C, Derangere V, Ryffel B, Kato M, Prevost-Blondel A, Ghiringhelli F, Apetoh L

Nat Immunol. 2014 Aug;15(8):758-66

Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.

Jary M, Ghiringhelli F, Jacquin M, Fein F, Nguyen T, Cleau D, Nerich V, El Gani M, Mathieu P, Valmary-Degano S, Arnould L, Lassabe C, Lamfichekh N, Fratte S, Paget-Bailly S, Bonnetain F, Borg C, Kim S

Cancer Chemother Pharmacol. 2014 Jul;74(1):141-50

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEFdagger.

Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Frappaz D, Taillia H, Schott R, Honnorat J, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O

Ann Oncol. 2014 Jul;25(7):1442-7

[Impact of chemotherapies on immunosuppression and discovery of new therapeutic targets].

Bruchard M, Ghiringhelli F

Bull Cancer. 2014 Jun;101(6):605-7

[Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan].

Boyer JC, Etienne-Grimaldi MC, Thomas F, Quaranta S, Picard N, Loriot MA, Poncet D, Gagnieu MC, Ged C, Broly F, Le Morvan V, Bouquie R, Gaub MP, Philibert L, Ghiringhelli F, Le Guellec C

Bull Cancer. 2014 Jun;101(6):533-53

Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.

Ghiringhelli F, Bichard D, Limat S, Lorgis V, Vincent J, Borg C, Berthou J, Orry D, Ortega-Deballon P, Lakkis Z, Facy O, Heyd B, Rat P, Nerich V, Ladoire S

Ann Surg Oncol. 2014 May;21(5):1632-40

[Tumor microenvironment: regulatory cells and immunosuppressive cytokines].

Bruchard M, Ghiringhelli F

Med Sci (Paris). 2014 Apr;30(4):429-35

Cell-death-associated molecular patterns as determinants of cancer immunogenicity.

Ladoire S, Hannani D, Vetizou M, Locher C, Aymeric L, Apetoh L, Kepp O, Kroemer G, Ghiringhelli F, Zitvogel L

Antioxid Redox Signal. 2014 Mar 1;20(7):1098-116

Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trials.

Ladoire S, Dalban C, Roche H, Spielmann M, Fumoleau P, Levy C, Martin AL, Ecarnot F, Bonnetain F, Ghiringhelli F

Eur J Cancer. 2014 Feb;50(3):506-16

Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients.

Rambach L, Bertaut A, Vincent J, Lorgis V, Ladoire S, Ghiringhelli F

World J Gastroenterol. 2014 Feb 14;20(6):1565-73

FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer.

Chaix M, Vincent J, Lorgis V, Ghiringhelli F

Oncology. 2014;87(3):148-58

Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients.

Mignot G, Hervieu A, Vabres P, Dalac S, Jeudy G, Bel B, Apetoh L, Ghiringhelli F

PLoS One. 2014 Aug 29;9(8):e105907

The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy.

Ghiringhelli F, Apetoh L

Expert Rev Clin Immunol. 2014 Jan;10(1):19-30

The role of reactive oxygen species and subsequent DNA-damage response in the emergence of resistance towards resveratrol in colon cancer models.

Colin DJ, Limagne E, Ragot K, Lizard G, Ghiringhelli F, Solary E, Chauffert B, Latruffe N, Delmas D

Cell Death Dis. 2014 Nov 20;5:e1533

Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma.

Wiazzane N, Chauffert B, Ghiringhelli F

Clin Res Hepatol Gastroenterol. 2013 Dec;37(6):614-8

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.

Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, Schlitzer A, Ginhoux F, Apetoh L, Chachaty E, Woerther PL, Eberl G, Bérard M, Ecobichon C, Clermont D, Bizet C, Gaboriau-Routhiau V, Cerf-Bensussan N, Opolon P, Yessaad N, Vivier E, Ryffel B, Elson CO, Doré J, Kroemer G, Lepage P, Boneca IG, Ghiringhelli F, Zitvogel L

Science. 2013 Nov;342(6161):971-6

Immune ambivalence: The schizophrenic bleomycin.

Mignot G, Bugaut H, Ghiringhelli F

Oncoimmunology. 2013 Sep 1;2(9):e25737

Improvement in survival of metastatic colorectal cancer: are the benefits of clinical trials reproduced in population-based studies?

Mitry E, Rollot F, Jooste V, Guiu B, Lepage C, Ghiringhelli F, Faivre J, Bouvier AM

Eur J Cancer. 2013 Sep;49(13):2919-25

Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma.

Darlix A, Baumann C, Lorgis V, Ghiringhelli F, Blonski M, Chauffert B, Zouaoui S, Pinelli C, Rech F, Beauchesne P, Taillandier L

Anticancer Res. 2013 Aug;33(8):3467-74.

Importance of lipid microdomains, rafts, in absorption, delivery, and biological effects of resveratrol.

Delmas D, Aires V, Colin DJ, Limagne E, Scagliarini A, Cotte AK, Ghiringhelli F

Ann N Y Acad Sci. 2013 Jul;1290:90-7

Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death.

Aires V, Limagne E, Cotte AK, Latruffe N, Ghiringhelli F, Delmas D

Mol Nutr Food Res. 2013 Jul;57(7):1170-81

Socs3 induction by PPARgamma restrains cancer-promoting inflammation.

Vegran F, Berger H, Ghiringhelli F, Apetoh L

Cell Cycle. 2013 Jul 15;12(14):2157-8.

SOCS3 transactivation by PPARgamma prevents IL-17-driven cancer growth.

Berger H, Vegran F, Chikh M, Gilardi F, Ladoire S, Bugaut H, Mignot G, Chalmin F, Bruchard M, Derangere V, Chevriaux A, Rebe C, Ryffel B, Pot C, Hichami A, Desvergne B, Ghiringhelli F, Apetoh L

Cancer Res. 2013 Jun 15;73(12):3578-90

Chemotherapy and immunomodulation: from immunogenic chemotherapies to novel therapeutic strategies.

Ghiringhelli F, Apetoh L

Future Oncol. 2013 Apr;9(4):469-72

Dacarbazine mediate antimelanoma effects via NK cells.

Hervieu A, Mignot G, Ghiringhelli F

Oncoimmunology. 2013 Apr 1;2(4):e23714.

Trans-10, cis-12 conjugated linoleic acid induced cell death in human colon cancer cells through reactive oxygen species-mediated ER stress.

Pierre AS, Minville-Walz M, Fevre C, Hichami A, Gresti J, Pichon L, Bellenger S, Bellenger J, Ghiringhelli F, Narce M, Rialland M

Biochim Biophys Acta. 2013 Apr;1831(4):759-68

Immune effects of 5-fluorouracil: Ambivalence matters.

Ghiringhelli F, Bruchard M, Apetoh L

Oncoimmunology. 2013 Mar 1;2(3):e23139.

Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.

Hervieu A, Rébé C, Végran F, Chalmin F, Bruchard M, Vabres P, Apetoh L, Ghiringhelli F, Mignot G

J. Invest. Dermatol.. 2013 Feb;133(2):499-508

Degarelix as a new antiangiogenic agent for metastatic colon cancer?

Ghiringhelli F, Isambert N, Ladoire S

World J Gastroenterol. 2013 Feb 7;19(5):769-72

Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells.

Bugaut H, Bruchard M, Berger H, Derangère V, Odoul L, Euvrard R, Ladoire S, Chalmin F, Végran F, Rébé C, Apetoh L, Ghiringhelli F, Mignot G

PLoS ONE. 2013 ;8(6):e65181

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.

Bruchard M, Mignot G, Derangère V, Chalmin F, Chevriaux A, Végran F, Boireau W, Simon B, Ryffel B, Connat JL, Kanellopoulos J, Martin F, Rébé C, Apetoh L, Ghiringhelli F

Nat. Med.. 2013 Jan;19(1):57-64

Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience.

Ghiringhelli F, Lorgis V, Vincent J, Ladoire S, Guiu B

Chemotherapy. 2013 ;59(5):354-60

Isolated lung perfusion as an adjuvant treatment of colorectal cancer lung metastases: a preclinical study in a pig model.

Pages PB, Facy O, Mordant P, Ladoire S, Magnin G, Lokiec F, Ghiringhelli F, Bernard A

PLoS One. 2013;8(3):e59485

STAT3 activation: A key factor in tumor immunoescape.

Rebe C, Vegran F, Berger H, Ghiringhelli F

JAKSTAT. 2013 Jan 1;2(1):e23010

Controversies on the role of Th17 in cancer: a TGF-beta-dependent immunosuppressive activity?

Martin F, Apetoh L, Ghiringhelli F

Trends Mol Med. 2012 Dec;18(12):742-9

High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study.

Facy O, Al Samman S, Magnin G, Ghiringhelli F, Ladoire S, Chauffert B, Rat P, Ortega-Deballon P

Ann Surg. 2012 Dec;256(6):1084-8

Metronomic cyclophosphamide with cisplatin and bevacizumab: a new chemotherapeutic regimen for refractory anaplastic ependymoma.

Lorgis V, Varbedian O, Ghiringhelli F

Anticancer Res. 2012 Nov;32(11):5067-70.

FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.

Ladoire S, Mignot G, Dalban C, Chevriaux A, Arnould L, Rebe C, Apetoh L, Boidot R, Penault-Llorca F, Fumoleau P, Roche H, Spielmann M, Levy C, Lortholary A, Eichler F, Mesleard C, Bonnetain F, Ghiringhelli F

Ann Oncol. 2012 Oct;23(10):2552-61

Immunomodulation and anti-inflammatory roles of polyphenols as anticancer agents.

Ghiringhelli F, Rebe C, Hichami A, Delmas D

Anticancer Agents Med Chem. 2012 Oct 1;12(8):852-73.

An immunosurveillance mechanism controls cancer cell ploidy.

Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M, Shen S, Marino G, Criollo A, Boileve A, Job B, Ladoire S, Ghiringhelli F, Sistigu A, Yamazaki T, Rello-Varona S, Locher C, Poirier-Colame V, Talbot M, Valent A, Berardinelli F, Antoccia A, Ciccosanti F, Fimia GM, Piacentini M, Fueyo A, Messina NL, Li M, Chan CJ, Sigl V, Pourcher G, Ruckenstuhl C, Carmona-Gutierrez D, Lazar V, Penninger JM, Madeo F, Lopez-Otin C, Smyth MJ, Zitvogel L, Castedo M, Kroemer G

Science. 2012 Sep 28;337(6102):1678-84.

Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.

Lorgis V, Chauffert B, Gentil J, Ghiringhelli F

Anticancer Res. 2012 Sep;32(9):4125-30.

Cardiac glycosides exert anticancer effects by inducing immunogenic cell death.

Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala AQ, Michaud M, Mignot G, Schlemmer F, Sulpice E, Locher C, Gidrol X, Ghiringhelli F, Modjtahedi N, Galluzzi L, Andre F, Zitvogel L, Kepp O, Kroemer G

Sci Transl Med. 2012 Jul 18;4(143):143ra99

Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells.

Terme M, Ullrich E, Aymeric L, Meinhardt K, Coudert JD, Desbois M, Ghiringhelli F, Viaud S, Ryffel B, Yagita H, Chen L, Mecheri S, Kaplanski G, Prevost-Blondel A, Kato M, Schultze JL, Tartour E, Kroemer G, Degli-Esposti M, Chaput N, Zitvogel L

Cancer Res. 2012 Jun 1;72(11):2757-67

Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies.

Ghiringhelli F, Vincent J, Guiu B, Chauffert B, Ladoire S

Invest New Drugs. 2012 Apr;30(2):758-64

Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts.

Lorgis V, Maura G, Coppa G, Hassani K, Taillandier L, Chauffert B, Apetoh L, Ladoire S, Ghiringhelli F

J Neurooncol. 2012 Apr;107(2):351-8

Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression.

Chalmin F, Mignot G, Bruchard M, Chevriaux A, Vegran F, Hichami A, Ladoire S, Derangere V, Vincent J, Masson D, Robson SC, Eberl G, Pallandre JR, Borg C, Ryffel B, Apetoh L, Rebe C, Ghiringhelli F

Immunity. 2012 Mar 23;36(3):362-73

Sodium citrate versus saline catheter locks for non-tunneled hemodialysis central venous catheters in critically ill adults: a randomized controlled trial.

Hermite L, Quenot JP, Nadji A, Barbar SD, Charles PE, Hamet M, Jacquiot N, Ghiringhelli F, Freysz M

Intensive Care Med. 2012 Feb;38(2):279-85

Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape.

Ghiringhelli F, Bruchard M, Chalmin F, Rebe C

J Biomed Biotechnol. 2012;2012:473712

Role of myeloid-derived suppressor cells in tumor immunotherapy.

Martin F, Apetoh L, Ghiringhelli F

Immunotherapy. 2012 Jan;4(1):43-57.

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice.

Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, Rello-Varona S, Tailler M, Menger L, Vacchelli E, Galluzzi L, Ghiringhelli F, di Virgilio F, Zitvogel L, Kroemer G

Science. 2011 Dec 16;334(6062):1573-7.

Discrepancy between in vitro and in vivo antitumor effect of a new platinum(II) metallointercalator.

Moretto J, Chauffert B, Ghiringhelli F, Aldrich-Wright JR, Bouyer F

Invest New Drugs. 2011 Dec;29(6):1164-76

Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma.

Boulin M, Guiu S, Chauffert B, Aho S, Cercueil JP, Ghiringhelli F, Krause D, Fagnoni P, Hillon P, Bedenne L, Guiu B

Anticancer Drugs. 2011 Sep;22(8):741-8.

Feasibility and safety of weekly sequential epirubicin-paclitaxel as adjuvant treatment for operable breast cancer patients older than 70 years.

Ladoire S, Rambach L, Quipourt V, Favier L, Ghiringhelli F, Arnould L, Pfitzenmeyer P, Fumoleau P, Coudert B

Clin Breast Cancer. 2011 Aug;11(4):235-40

In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.

Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rebe C, Coudert B, Martin F, Bizollon MH, Vanoli A, Coutant C, Fumoleau P, Bonnetain F, Ghiringhelli F

J Pathol. 2011 Jul;224(3):389-400

Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer.

Ladoire S, Martin F, Ghiringhelli F

Cancer Immunol Immunother. 2011 Jul;60(7):909-18

Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies.

Apetoh L, Vegran F, Ladoire S, Ghiringhelli F

Curr Mol Med. 2011 Jul 1;11(5):365-72.

T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival.

Ladoire S, Arnould L, Mignot G, Apetoh L, Rebe C, Martin F, Fumoleau P, Coudert B, Ghiringhelli F

Br J Cancer. 2011 Jul 26;105(3):366-71

Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.

Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, Boucontet L, Apetoh L, Ghiringhelli F, Casares N, Lasarte JJ, Matsuzaki G, Ikuta K, Ryffel B, Benlagha K, Tesniere A, Ibrahim N, Dechanet-Merville J, Chaput N, Smyth MJ, Kroemer G, Zitvogel L

J Exp Med. 2011 Mar 14;208(3):491-503

Tumor exosome-mediated MDSC activation.

Mignot G, Chalmin F, Ladoire S, Rebe C, Ghiringhelli F

Am J Pathol. 2011 Mar;178(3):1403-4; author reply 1404-5.

Harnessing dendritic cells in cancer.

Apetoh L, Locher C, Ghiringhelli F, Kroemer G, Zitvogel L

Semin Immunol. 2011 Feb;23(1):42-9

Comparison of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a murine model of peritoneal carcinomatosis.

Facy O, Radais F, Ladoire S, Delroeux D, Tixier H, Ghiringhelli F, Rat P, Chauffert B, Ortega-Deballon P

J Exp Clin Cancer Res. 2011 Jan 7;30:4.

Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.

Ladoire S, Arnould L, Mignot G, Coudert B, Rebe C, Chalmin F, Vincent J, Bruchard M, Chauffert B, Martin F, Fumoleau P, Ghiringhelli F

Breast Cancer Res Treat. 2011 Jan;125(1):65-72

Transport, stability, and biological activity of resveratrol.

Delmas D, Aires V, Limagne E, Dutartre P, Mazué F, Ghiringhelli F, Latruffe N

Ann. N. Y. Acad. Sci.. 2011 Jan;1215:48-59

Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents.

Ladoire S, Bonnetain F, Gauthier M, Zanetta S, Petit JM, Guiu S, Kermarrec I, Mourey E, Michel F, Krause D, Hillon P, Cormier L, Ghiringhelli F, Guiu B

Oncologist. 2011;16(1):71-81

Desirable cell death during anticancer chemotherapy.

Locher C, Conforti R, Aymeric L, Ma Y, Yamazaki T, Rusakiewicz S, Tesniere A, Ghiringhelli F, Apetoh L, Morel Y, Girard JP, Kroemer G, Zitvogel L

Ann N Y Acad Sci. 2010 Oct;1209:99-108

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

Ladoire S, Eymard JC, Zanetta S, Mignot G, Martin E, Kermarrec I, Mourey E, Michel F, Cormier L, Ghiringhelli F

Anticancer Res. 2010 Oct;30(10):4317-23.

Preoperative radiochemotherapy for resectable localised oesophageal cancer: a controversial strategy.

Crehange G, Bonnetain F, Peignaux K, Truc G, Blanchard N, Rat P, Chauffert B, Ghiringhelli F, Maingon P

Crit Rev Oncol Hematol. 2010 Sep;75(3):235-42

Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.

Ladoire S, Beynat C, Diaz P, Coudert B, Favier L, Ghiringhelli F

Med Oncol. 2010 Sep;27(3):938-41

Visceral fat and bevacizumab in metastatic colorectal cancer - Authors' response.

Bonnetain F, Guiu B, Ghiringhelli F

Gut. 2010;59:1450

Human FOXP3 and cancer.

Martin F, Ladoire S, Mignot G, Apetoh L, Ghiringhelli F

Oncogene. 2010 Jul 22;29(29):4121-9

Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study.

Khouri C, Guiu B, Cercueil JP, Chauffert B, Ladoire S, Ghiringhelli F

Anticancer Drugs. 2010 Jul;21(6):656-61

Chemotherapy and radiotherapy: cryptic anticancer vaccines.

Ma Y, Kepp O, Ghiringhelli F, Apetoh L, Aymeric L, Locher C, Tesniere A, Martins I, Ly A, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L

Semin Immunol. 2010 Jun;22(3):113-24

[Myeloid-derived suppressor cells: a key player in cancer]

Chalmin F, Mignot G, Ghiringhelli F

Med Sci (Paris). 2010 Jun-Jul;26(6-7):576-9.

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.

Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rebe C, Ghiringhelli F

Cancer Res. 2010 Apr 15;70(8):3052-61

Hepatic arterial infusion of gemcitabine-oxaliplatin in a large metastasis from colon cancer

Guiu B, Vincent J, Guiu S, Ladoire S, Ortega-Deballon P, Cercueil JP, Chauffert B, Ghiringhelli F

World J Gastroenterol. 2010 Mar 7;16(9):1150-4.

Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer.

Guiu B, Petit JM, Bonnetain F, Ladoire S, Guiu S, Cercueil JP, Krause D, Hillon P, Borg C, Chauffert B, Ghiringhelli F

Gut. 2010 Mar;59(3):341-7

Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells.

Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, Boireau W, Rouleau A, Simon B, Lanneau D, De Thonel A, Multhoff G, Hamman A, Martin F, Chauffert B, Solary E, Zitvogel L, Garrido C, Ryffel B, Borg C, Apetoh L, Rebe C, Ghiringhelli F

J Clin Invest. 2010 Feb 1;120(2):457-71

Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity.

Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, Martins I, Kroemer G, Smyth MJ, Zitvogel L

Cancer Res. 2010 Feb 1;70(3):855-8

Dual role of heat shock proteins as regulators of apoptosis and innate immunity.

Joly AL, Wettstein G, Mignot G, Ghiringhelli F, Garrido C

J Innate Immun. 2010;2(3):238-47

Immunogenic death of colon cancer cells treated with oxaliplatin.

Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, Mendiboure J, Pignon JP, Jooste V, van Endert P, Ducreux M, Zitvogel L, Piard F, Kroemer G

Oncogene. 2010 Jan 28;29(4):482-91

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors.

Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, Uhl M, Genin P, Civas A, Ryffel B, Kanellopoulos J, Tschopp J, Andre F, Lidereau R, McLaughlin NM, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L

Nat Med. 2009 Oct;15(10):1170-8

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.

Banissi C, Ghiringhelli F, Chen L, Carpentier AF

Cancer Immunol Immunother. 2009 Oct;58(10):1627-34

Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study.

Ghiringhelli F, Guiu B, Chauffert B, Ladoire S

World J. Gastroenterol.. 2009 Sep;15(34):4278-83

Witch hunt against tumor cells enhanced by dendritic cells.

Locher C, Rusakiewicz S, Tesniere A, Ghiringhelli F, Apetoh L, Kroemer G, Zitvogel L

Ann N Y Acad Sci. 2009 Sep;1174:51-60.

What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?

Robert C, Ghiringhelli F

Oncologist. 2009 Aug;14(8):848-61

DNA-damaged polyploid cancer cells can reverse to diploidy: an ordered, but little understood, process of genomic reduction [with reference to the previous comments of Forer (2008) and Wheatley (2008a and b)].

Martin F, Puig PE, Ghiringhelli F, Chauffert B

Cell Biol Int. 2009 Jun;33(6):702-3

Pilot study of transarterial chemoembolization with pirarubicin and amiodarone for unresectable hepatocellular carcinoma.

Guiu B, Colin C, Cercueil JP, Loffroy R, Guiu S, Ferrant E, Jouve JL, Bonnetain F, Boulin M, Ghiringhelli F, Minello A, Hillon P, Bedenne L, Krause D, Chauffert B

Am J Clin Oncol. 2009 Jun;32(3):238-44.

Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.

Ménard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C, Nonn C, Chaput N, Taïeb J, Delahaye NF, Flament C, Emile JF, Le Cesne A, Zitvogel L

Cancer Res.. 2009 Apr;69(8):3563-9

Carcinomatous Meningitis from Unknown Primary Carcinoma.

Favier L, Ladoire L, Guiu B, Arnould L, Guiu S, Boichot C, Isambert N, Besancenot JF, Muller M, Ghiringhelli F

Case Rep Oncol. 2009 Oct 10;2(3):177-183.

Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity.

Menard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F

Cancer Immunol Immunother. 2008 Nov;57(11):1579-87

CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer.

Roux S, Apetoh L, Chalmin F, Ladoire S, Mignot G, Puig PE, Lauvau G, Zitvogel L, Martin F, Chauffert B, Yagita H, Solary E, Ghiringhelli F

J. Clin. Invest.. 2008 Nov;118(11):3751-61

Immunogenic cancer cell death: a key-lock paradigm.

Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, Schlemmer F, Zitvogel L, Kroemer G

Curr Opin Immunol. 2008 Oct;20(5):504-11

[Immunological aspects of anticancer chemotherapy]

Zitvogel L, Tesniere A, Apetoh L, Ghiringhelli F, Kroemer G

Bull Acad Natl Med. 2008 Oct;192(7):1469-87; discussion 1487-9.

Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy.

Puig PE, Guilly MN, Bouchot A, Droin N, Cathelin D, Bouyer F, Favier L, Ghiringhelli F, Kroemer G, Solary E, Martin F, Chauffert B

Cell Biol Int. 2008 Sep;32(9):1031-43

Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses.

Roux S, Bernat C, Al-Sakere B, Ghiringhelli F, Opolon P, Carpentier AF, Zitvogel L, Mir LM, Robert C

Cancer Immunol. Immunother.. 2008 Sep;57(9):1291-300

Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?

Menard C, Ghiringhelli F, Roux S, Chaput N, Mateus C, Grohmann U, Caillat-Zucman S, Zitvogel L, Robert C

Clin Cancer Res. 2008 Aug 15;14(16):5242-9.

Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies.

Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L

Cancer Res. 2008 Jun 1;68(11):4026-30.

The anticancer immune response: indispensable for therapeutic success?

Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G

J Clin Invest. 2008 Jun;118(6):1991-2001.

Cancer is not just a disease of a tissue: it is a host disease. How to reactivate host defense against tumors using conventional therapies of cancer?

Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Mignot G, Ullrich E, Kroemer G, Zitvogel L

Ann. Endocrinol. (Paris). 2008 Apr;69(2):151-2

Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells.

Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B, Fumoleau P, Ghiringhelli F

Clin Cancer Res. 2008 Apr 15;14(8):2413-20.

Immunological aspects of cancer chemotherapy.

Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G

Nat Rev Immunol. 2008 Jan;8(1):59-73.

Molecular characteristics of immunogenic cancer cell death.

Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G

Cell Death Differ. 2008 Jan;15(1):3-12

Ecto-calreticulin in immunogenic chemotherapy.

Obeid M, Tesniere A, Panaretakis T, Tufi R, Joza N, van Endert P, Ghiringhelli F, Apetoh L, Chaput N, Flament C, Ullrich E, de Botton S, Zitvogel L, Kroemer G

Immunol. Rev.. 2007 Dec;220:22-34

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.

Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S, André F, Tursz T, Kroemer G, Zitvogel L

Immunol. Rev.. 2007 Dec;220:47-59

Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference.

Chaput N, De Botton S, Obeid M, Apetoh L, Ghiringhelli F, Panaretakis T, Flament C, Zitvogel L, Kroemer G

J Mol Med. 2007 Oct;85(10):1069-76

Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic.

Obeid M, Panaretakis T, Tesniere A, Joza N, Tufi R, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G

Cancer Res. 2007 Sep 1;67(17):7941-4.

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L

Nat Med. 2007 Sep;13(9):1050-9

[Case-control study evaluating the incidence of hyperhomocysteinemia in cancer patients in an internal medicine department]

Falvo N, Ghiringhelli F, Berthier S, Bonnotte B, Lorcerie B

Rev Med Interne. 2007 Aug;28(8):520-5

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.

Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B

Cancer Immunol Immunother. 2007 May;56(5):641-8

Links between innate and cognate tumor immunity.

Ghiringhelli F, Apetoh L, Housseau F, Kroemer G, Zitvogel L

Curr Opin Immunol. 2007 Apr;19(2):224-31

Immunogenic chemotherapy: discovery of a critical protein through proteomic analyses of tumor cells.

Apetoh L, Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Piacentini M, Kroemer G, Zitvogel L

Cancer Genomics Proteomics. 2007 Mar-Apr;4(2):65-70.

[Calreticulin dictates the immunogenicity of anti-cancer chemotherapy and radiotherapy]

Apetoh L, Ghiringhelli F, Zitvogel L

Med Sci (Paris). 2007 Mar;23(3):257-8.

Calreticulin exposure dictates the immunogenicity of cancer cell death.

Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G

Nat Med. 2007 Jan;13(1):54-61

The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression.

Ghiringhelli F, Ménard C, Martin F, Zitvogel L

Immunol. Rev.. 2006 Dec;214:229-38

Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma.

Schmitt E, Maingret L, Puig PE, Rerole AL, Ghiringhelli F, Hammann A, Solary E, Kroemer G, Garrido C

Cancer Res. 2006 Apr 15;66(8):4191-7.

Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines.

Taieb J, Chaput N, Schartz N, Roux S, Novault S, Menard C, Ghiringhelli F, Terme M, Carpentier AF, Darrasse-Jeze G, Lemonnier F, Zitvogel L

J Immunol. 2006 Mar 1;176(5):2722-9.

A novel dendritic cell subset involved in tumor immunosurveillance.

Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M, Pequignot M, Casares N, Terme M, Flament C, Opolon P, Lecluse Y, Metivier D, Tomasello E, Vivier E, Ghiringhelli F, Martin F, Klatzmann D, Poynard T, Tursz T, Raposo G, Yagita H, Ryffel B, Kroemer G, Zitvogel L

Nat Med. 2006 Feb;12(2):214-9

[Vaccine strategies against melanoma].

Ghiringhelli F, Zitvogel L

Med Sci (Paris). 2006 Feb;22(2):183-7.

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death.

Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, Coutant F, Metivier D, Pichard E, Aucouturier P, Pierron G, Garrido C, Zitvogel L, Kroemer G

J Exp Med. 2005 Dec 19;202(12):1691-701.

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.

Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, Lecesne A, Robert C, Blay JY, Bernard J, Caillat-Zucman S, Freitas A, Tursz T, Wagner-Ballon O, Capron C, Vainchencker W, Martin F, Zitvogel L

J Exp Med. 2005 Oct 17;202(8):1075-85.

Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.

Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E, Kroemer G, Martin F, Chauffert B, Zitvogel L

J Exp Med. 2005 Oct 3;202(7):919-29

[Treatment of cancer and hematological malignancy in elderly people (Part II)].

Ladoire S, Ghiringhelli F, Manckoundia P, Casasnovas RO, Solary E, Besancenot JF, Pfitzenmeyer P

Rev Med Interne. 2005 Apr;26(4):304-14

[Treatment of cancer and hematological malignancy in elderly people: oncogeriatrics as a discipline for the future (Part I): geriatric evaluation and management of solid tumors].

Ghiringhelli F, Ladoire S, Manckoundia P, Chauffert B, Solary E, Besancenot JF, Pfitzenmeyer P

Rev Med Interne. 2005 Mar;26(3):216-25

Increased immunogenicity of colon cancer cells by selective depletion of cytochrome C.

Schmitt E, Parcellier A, Ghiringhelli F, Casares N, Gurbuxani S, Droin N, Hamai A, Pequignot M, Hammann A, Moutet M, Fromentin A, Kroemer G, Solary E, Garrido C

Cancer Res.. 2004 Apr;64(8):2705-11

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.

Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F

Eur. J. Immunol.. 2004 Feb;34(2):336-44

Freshly isolated bone marrow cells induce death of various carcinoma cell lines.

Larmonier N, Ghiringhelli F, Larmonier CB, Moutet M, Fromentin A, Baulot E, Solary E, Bonnotte B, Martin F

Int. J. Cancer. 2003 Dec;107(5):747-56

[Microbeads, nanobeads and cytometry: applications to the analysis and purification of cells and biomolecules].

Lizard G, Duvillard L, Wedemeyer N, Muller C, Ghiringhelli F, Cesbron A, Poncelet P, Gallet F, Kahn E, Gambert P, Göhde W

Pathol. Biol.. 2003 Sep;51(7):418-27

Human ectonucleotidase-expressing CD25(high) Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions.

Thibaudin M, Chaix M, Boidot R, Végran F, Derangère V, Limagne E, Berger H, Ladoire S, Apetoh L, Ghiringhelli F

Oncoimmunology. ;5(1):e1055444

Induction of pyroptosis in colon cancer cells by LXRβ.

Rébé C, Derangère V, Ghiringhelli F

Mol Cell Oncol. ;2(1):e970094

[Immunoediting eventually proven in humans. Genetics to assist immunotherapy].

David Fumet J, Ghiringhelli F

Med Sci (Paris). ;35(8-9):629-631